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estrutura bio-híbrida, ácido fólico, interacção biotina-avidina, 
direccionamento selectivo  
 
Neste trabalho foram fabricadas estruturas bio-híbridas (BHS) à base 
de glicopolímeros dendríticos biotinilados e estreptavidina as quais 
foram posteriormente funcionalizadas com o ácido fólico com vista ao 
reconhecimento preferencial por células tumorais. A estratégia de 
fabricação recorreu, em ambos os casos, a interações não-covalentes. 
A caracterização das estruturas no que respeita ao seu tamanho 
hidrodinâmico e potencial zeta, em conjunto com os estudos de 
citotoxicidade, foram realizados no sentido de avaliar as propriedades 
físicas, assim como a biocompatibilidade das estruturas. Os resultados 
obtidos demonstraram que BHS estáveis, com tamanhos definidos, 
podem ser obtidas através de poliassociação controlada. Além disso, 
nas condições experimentais consideradas, as BHS apresentam 
biocompatibilidade e não apresentam toxicidade para as células.   
Seguidamente, avaliou-se a influência do ligando do ácido fólico sobre 
a segmentação de células cancerígenas ricas em receptores de folato 
por citometria de fluxo. Para tal, foi avaliado o efeito da quantidade de 
ácido fólico, do comprimento da cadeia de PEG (espaçador) e da 
concentração de BHS, tal como o impacto das estratégias de 
purificação.  
Adicionalmente foi ainda estudado o mecanismo de absorção celular.
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In this work, biohybrid structures (BHS) based on streptavidin and 
pentavalent biotinylated dendritic glycopolymer were fabricated 
through non-covalent streptavidin-biotin conjugation and further 
functionalized with the folic acid for the selective targeting to tumor 
cells. Characterization of the hydrodynamic size and zeta potential of 
the structures together with the cytotoxicity studies were performed to 
assess the physical properties and biocompatibility of the structures. It 
was shown that stable BHS with defined sizes can be obtained due to a 
controlled polyassociation reaction. Furthermore, BHS are 
biocompatible and do not cause toxicity to the cells under the given 
experimental conditions.  
Next, the effect of the folic acid ligand on the targeting function 
towards folate receptor expressing cancer cells was studied in flow 
cytometry experiments. For this purpose the amount of folic acid, the 
length of the PEG-chain / spacer, and the type of protein used were 
evaluated, as well as the impact of purification strategies. Additionally, 
the cell uptake mechanism was also briefly looked into.  
I 
 
Table of Contents 
 
I. Theoretical introduction ....................................................................................................... 1 
1. Dendritic polymers .......................................................................................................... 1 
1.1. Glycopolymers .......................................................................................................... 4 
2. Used proteins ................................................................................................................... 6 
2.1. Avidin ........................................................................................................................ 6 
2.1.1. Streptavidin ............................................................................................................ 8 
2.1.2. Neutravidin ............................................................................................................ 9 
3.   Molecular recognition of folic acid by folate receptors ................................................... 10 
4.  Biohybrid structures .......................................................................................................... 13 
4.1. Conjugation chemistry in biohybrid materials ........................................................ 14 
4.1.1. Covalent binding ................................................................................................. 14 
4.1.2. Non covalent interactions .................................................................................... 14 
4.1.2.1. β-Cyclodextrin-adamantane host−guest interactions ................................... 15 
4.1.2.2. Concanavalin A – sugars .............................................................................. 16 
4.1.2.3. Biotin – avidin chemistry ............................................................................. 17 
5. Methods ......................................................................................................................... 20 
5.1. Dynamic light scattering ......................................................................................... 20 
5.2. Zeta potential ........................................................................................................... 21 
5.3. Alamar Blue Assay.................................................................................................. 22 
5.4. Flow cytometry ....................................................................................................... 23 
II. Aim of the thesis ............................................................................................................ 26 
II 
 
III. Results and discussion ................................................................................................... 28 
1. Introduction to biohybrid structures .............................................................................. 28 
2. Characterization of the BHS size by DLS ..................................................................... 30 
2.1. Formation of the BHS ............................................................................................. 30 
2.2. Comparison between BHS fabricated with different ratios of SA/PEI-biotin ........ 31 
2.3. Size of non-modified and modified BHS ................................................................ 32 
2.4. Stability of non-modified and modified BHS ......................................................... 35 
2.4.1. Long term stability of the structures ................................................................ 35 
2.4.2. Stability against the excess of biotin ................................................................ 36 
3. Characterization of BHS by zeta potential .................................................................... 38 
4. Cell viability .................................................................................................................. 39 
5. Flow cytometry .............................................................................................................. 45 
5.1. Non-modified biohybrid structures based on PEI-biotin/SA and PEI-biotin/NA ... 46 
5.2. BHS modified with short folate moieties ................................................................ 49 
5.3. BHS modified with long folate moieties ................................................................. 54 
5.4. Comparison between the BHS modified with short and long folate moieties ........ 57 
5.5. BHS modified with Biotin-PEG and BHS modified with folate ............................ 58 
5.6. Cellular uptake mechanism ..................................................................................... 62 
IV. Conclusion ..................................................................................................................... 66 
V. Experimental section ..................................................................................................... 69 
1. Reagents and materials .................................................................................................. 69 
2. Instruments .................................................................................................................... 70 
2.1. Dynamic light scattering and zeta potential ............................................................ 70 
2.2. UV-Vis spectroscopy .............................................................................................. 70 
III 
 
2.3. Cell culture .............................................................................................................. 70 
2.4. Cytotoxicity ............................................................................................................. 70 
2.5. Flow cytometry ....................................................................................................... 71 
3. Formation of biohybrid structures ................................................................................. 71 
4. Characterization of biohybrid structures ....................................................................... 73 
4.1. Dynamic light scattering ......................................................................................... 73 
4.2. Zeta potential ........................................................................................................... 74 
4.3. Cell culture .............................................................................................................. 74 
4.4. Cytotoxicity assay ................................................................................................... 74 
4.5. Flow cytometry ....................................................................................................... 74 
VI. References ..................................................................................................................... 76 
VII. Appendix ....................................................................................................................... 84 
 
 
 
 
 
 
 
 
 
 
IV 
 
List of abbreviations 
AF4 
BHS 
Biotin-PEG 
Con A 
DB  
DF 
DLS 
DMEM 
DPBS 
EDL 
EPR 
FITC 
Folate 
FR 
HABA 
HEK293 
MFI  
NA 
Asymmetric flow field flow fractionation  
Biohybrid structure 
Biotin-PEG-COOH 
Concanavalin A 
Degree of branching 
Degree of functionalization 
Dynamic Light Scattering 
Dulbecco’s modified eagle medium 
Dulbecco’s phosphate buffered saline 
Electrical double layer 
Enhanced permeability and retention effect 
Fluorescein isothiocyanate 
Biotin-PEG-Folic acid 
Folate receptors 
2-(4’-hydroxyazobenzene) benzoic acid 
Human Embryonic Kidney 293 cells 
Mean fluorescence intensity 
Neutravidin 
V 
 
NP 
PAMAM 
PBS 
PCS 
PEG 
PEI 
PPI 
RFC  
QELS 
SA 
SBC-2 
Nanoparticle 
Poly(amido amine) 
Phosphate Buffered Saline 
Photon correlation spectroscopy 
Poly(ethylene glycol) 
Hyperbranched poly(ethylene imine) 
Poly(propylene imine) 
Reduced Folate Carrier 
Quasi-elastic light scattering  
Streptavidin 
Human Cervix Carcinoma cells
 
 
 
 
 
  
VI 
 
List of figures 
Figure 1: Different structural components of the dendrimer ....................................................... 1 
Figure 2: Schematic presentation  of  PEI dendrimers with different degrees of oligosaccharide 
functionalization. Branching units: L= linear unit; T= terminal unit and D = dendritic unit ...... 5 
Figure 3: Structure of avidin. Monomer unit (left) and natural tetramer (right). ........................ 7 
Figure 4: Scheme  presenting  the  ability  of  HABA  to  determine  biotin  binding  activity of 
avidin in solution ......................................................................................................................... 8 
Figure 5: Structure of Streptavidin. Monomer unit (left), Tetramer unit with biotin molecules. 9 
Figure 6: Concept  of  tumor-targeting  nanoparticles.  (a)  EPR   effect.  Leaky  vasculature  in 
tumor  cells  compared  to  healthy  cells,  owing to fenestrations and gaps between endothelial 
cells   that  result  from   abnormal  angiogenesis.  Nanoparticles  in  circulation  can  passively 
extravagate  through  these  gaps  and  enter  the  tumor  interstitium.  (b)  Molecular targeting. 
Nanoparticles  with  folate  ligands  targeted   toward  folate  receptors  overexpressed  on   the 
surface of  tumor  cells  can be used  to actively enhance accumulation of the drug at the tumor 
site and can also help to internalize nanoparticles into cells via endocytosis ........................... 11 
Figure 7: Folate-mediated  delivery  of  therapeutic  agents  to  cancer  cells  expressing  folate 
receptors.  Two   types  of  strategies  can   be  envisioned:  a   fraction  of   the  drug  carrying 
nanoparticle (NP)  functionalized  with  folic acid will traffic into  the cancer cells by receptor-
mediated  endocytosis  (left side  of diagram), while  the rest will  remain  on the  cell surfaces 
(right side of diagram) ............................................................................................................... 13 
Figure 8: Schematic of adamantane and β-cyclodextrin inclusion complex formation ............ 15 
VII 
 
Figure 9: Possible   methods  of  bioconjugation   using   biotin-avidin   chemistry.  1  and   3 – 
modification through biotinylation of functional groups. 2 – direct modification of avidin..... 18 
Figure 10: Schematic representation of the electric double layer ............................................. 22 
Figure 11: Alamar  Blue   assay  principle.  Reduction   of  resazurin  converts   the  essentially 
nonfluorescent dye to the highly pink fluorescent resorufin ..................................................... 23 
Figure 12:  Principle   of  a   flow  cytometer.  A  single  cell  suspension  is  hydrodynamically 
focused  with fluid stream to  intersect a light source. Signals are  collected by a forward angle 
light  scatter detector, a  sidescatter detector (1),  and  multiple fluorescence emission detectors 
(2–4). The signals are amplified and converted to digital signal and displayed on the computer.
 ................................................................................................................................................... 24 
Figure 13: Schematic   presentation   of    the   biohybrid   structure  consisted   of  biotinylated 
glycopolymer  and  streptavidin  and  modified  with  folic  acid  fabricated  in the frame of the 
thesis. ......................................................................................................................................... 27 
Figure 14: Synthesis scheme of the biohybrid structures modified with the folic acid. ........... 28 
Figure 15: Size of the single components and the biohybrid structures .................................... 30 
Figure 16: Comparison of the BHS size fabricated from different ratios of SA/PEI-biotin ..... 31 
Figure 17: Comparison of the size of non-modified and modified with folate BHS ................ 33 
Figure 18: Long term stability study of the non-modified BHS consisted of SA/PEI-biotin 1/1.
 ................................................................................................................................................... 35 
Figure 19: Long term stability study of the purified BHS modified with Folate5k. ................. 36 
Figure 20: Size of the structures with additional biotin molecules. B = Biotin ........................ 37 
Figure 21: Size  of the structures with  additional biotin-PEG molecules. BPEG = Biotin-PEG.
 ................................................................................................................................................... 37 
VIII 
 
Figure 22: Zeta potential measurement of BHS modified with Folate2k.................................. 39 
Figure 23: Viabilities    of   HEK293   and   SBC-2   cells   treated   for   24   h   with  different 
concentrations of PEI-biotin. ..................................................................................................... 40 
Figure 24: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS. .............................................................................................................. 40 
Figure 25: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS modified with Folate2k after the purification ...................................... 41 
Figure 26: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS modified with Folate2k without the purification. ................................ 41 
Figure 27: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS modified with Folate5k after the purification. ..................................... 42 
Figure 28: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS modified with Folate5k without the purification. ................................ 43 
Figure 29: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS modified with Biotin-PEG2k. .............................................................. 44 
Figure 30: Viabilities   of   HEK293   and   SBC-2   cells   treated   for   24   h   with   different 
concentrations of BHS modified with Biotin-PEG5k. .............................................................. 44 
Figure 31: Cellular uptake after incubation with non-modified BHS and single components for 
4h. .............................................................................................................................................. 46 
Figure 32: Cellular uptake BHS based on PEI-biotin/SA after different incubation times ....... 47 
Figure 33: Cellular uptake of HEK293 cells after different incubation times........................... 48 
Figure 34: Cellular uptake of SBC-2 cells after different incubation times. ............................. 48 
IX 
 
Figure 35: Cellular  uptake   after  incubation  with  BHS   modified  with  Folate2k   or  single 
components for 4 h. BHS2k = PEI-biotin/SA/Folate2k, non-pur. = non-purified .................... 50 
Figure 36: Cell internalization pathways for HEK293 and SBC-2 cells. .................................. 51 
Figure 37: Cellular  uptake of  HEK293  cells after  different  incubation  times. BHS2k = PEI-
biotin/SA/Folate2k, non-pur. = non-purified. ............................................................................ 52 
Figure 38: Cellular  uptake  of  SBC-2  cells  after  different  incubation  times.  BHS2k = PEI-
biotin/SA/Folate2k, non-pur. = non-purified. ............................................................................ 53 
Figure 39: Cellular  uptake   after  incubation   with  BHS  modified  with  Folate5k  or   single 
components for 1 h. BHS5k = PEI-biotin/SA/Folate5k, non-pur. = non-purified .................... 54 
Figure 40: Cellular  uptake  of  HEK293  cells  after different  incubation times. BHS5k = PEI-
biotin/SA/Folate5k, non-pur. = non-purified ............................................................................. 55 
Figure 41: Cellular  uptake  of  SBC-2  cells  after  different  incubation  times.  BHS5k = PEI-
biotin/SA/Folate5k, non-pur. = non-purified ............................................................................. 56 
Figure 42: Cellular  uptake  of  HEK293  and  SBC  cells  after  incubation  with  purified PEI-
biotin/SA/Folate 1/1/6 with different chain lengths after different incubation times ............... 57 
Figure 43: Cellular  uptake  of  HEK293  and  SBC  cells  after  incubation  with  purified PEI-
biotin/SA/Folate 1/1/10 with different chain lengths after different incubation times. ............ 58 
Figure 44: The overview of different modifications of BHS. ................................................... 59 
Figure 45: Cellular uptake after incubation with BHS modified with folate and Biotin-PEG for 
8h. BHS = PEI-biotin/SA, non-pur. = non-purified. ................................................................. 60 
Figure 46: Cellular uptake of HEK293 cells after different incubation times........................... 61 
Figure 47: Cellular uptake of SBC-2 cells after different incubation times .............................. 62 
Figure 48: Clathrin-dependent and -independent internalization pathways .............................. 63 
X 
 
Figure 49: Cellular  uptake  after  incubation  with  non-modified BHS incubated and different 
concentrations of inhibitors of endocytosis for 0.5 h. chl. = chlorpromazine ........................... 64 
Figure 50: Cellular  uptake  after  incubation  with  BHS  modified with Folate2k and different 
concentrations  of  inhibitors  of endocytosis  for 2 h. BHS2k = PEI-biotin/SA/Folate2k, chl. = 
chlorpromazine .......................................................................................................................... 64 
Figure 51: Summary  of the influencing key points in  the conjugation of biotinylated dendritic 
glycopolymers and streptavidin ................................................................................................. 67 
Figure 52: Long  term stability study  of  the  non-modified  BHS  consisted  of  SA/PEI-biotin 
1/0.5. .......................................................................................................................................... 84 
Figure 53: Long term stability study of the non-modified BHS consisted of SA/PEI-biotin 1/2.
 ................................................................................................................................................... 84 
Figure 54: Long term stability study of the purified BHS modified with Folate2k. ................. 85 
Figure 55: Long term stability study of the non-purified BHS modified with Folate2k. .......... 85 
Figure 56: Long term stability study of the non-purified BHS modified with Folate5k. .......... 86 
Figure 57: Zeta potential of BHS modified with Folate5k. ....................................................... 86 
Figure 58: Viability of HEK293 cells after 24 hours incubation with different structures. ...... 87 
Figure 59: Viability of SBC-2 cells after 24 hours incubation with different structures. ......... 87 
Figure 60: Viabilities   of    HEK293   and   SBC-2   cells    treated   for   24h   with    different 
concentrations of chlorp romazine. ........................................................................................... 88 
 
 
 
XI 
 
List of tables  
Table 1. Properties of different biotin-binding proteins………………………………………10 
Table 2. Overview of the components and biohybrid structures……………………………...29 
Table 3. Comparison between molar ratio and ligand stoichiometry of BHS with different 
SA/PEI-biotin ratio. Mass concentration is given for the structures with the molar mass of SA 
2.5 g∙mol-1 and the corresponding PEI-biotin concentration………………………………….32 
Table 4. List of the used substances and their suppliers………………………………………69 
Table 5. Molar concentrations used for fabrication of BHS in DLS measurements………….72 
Table 6. Molar ratios of the PEI-biotin/SA/Folate and PEI-biotin/SA/biotin-PEG used in 
different experiments………………………………………………………………………….73 
 
 
 
 
 
 
 
 
 
1 
 
I. Theoretical introduction 
1. Dendritic polymers 
The high increase of interest in dendrimer’s research over the last decade made dendrimer 
chemistry one of the most rapidly expanding areas of science. Dendrimers are nano-sized, 
radially symmetric molecules with a well-defined, homogeneous, and monodisperse structure 
consisting of tree-like arms or branches.[1] The word dendrimer originates from the 
combination of the Greek words ‘dendron’ meaning tree or branch, and ‘meros’ referring to 
part.[2] 
 
Figure 1: Different structural components of the dendrimer.[3]  
 
These types of molecules were discovered by Fritz Vögtle and his co-workers in 1978 when 
the first fully controlled synthesis of a dendrimer was conducted.[4] In the 1990s the 
widespread potential of these hyperbranched structures began to be appreciated and the 
number of publications in this field of research started to significantly increase.[5] The wide 
range of potential applications of these new functional materials is a consequence of their 
unique structure. Dendrimers are complex molecules with a well-defined architecture. They 
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possess three distinguishing structural components, namely (a) an initiator core, (b) an interior 
layer consisting of repeating branching units, radially attached to the core (generations), and 
(c) exterior (terminal groups) attached to the outermost interior generation that can modify the 
physicochemical or biological properties of dendrimers.[6] A typical dendrimer structure is 
presented in Figure 1.  
Dendrimers can be synthesized via two different synthesis strategies, namely the divergent 
approach and the convergent approach. The divergent approach is a stepwise layer-by-layer 
synthesis that starts from the focal core and builds up the molecule towards the periphery. It is 
based on a pair of basic operations - ‘growth of a generation’, that consists of coupling of the 
branching centers, and deprotection or modification of end-functionalities of the periphery to 
create new reactive surface functionalities. An alternative method of dendrimer synthesis is 
the convergent approach, in which the reaction begins from the exterior, starting with the 
molecular structure that ultimately becomes the outermost arm of a dendron. When the 
growing dendrons are large enough, several are attached to a suitable core to give a complete 
dendrimer.[7] 
The most valuable advantages of dendrimers are the high amount of terminal groups and low 
viscosity, however their multistep synthesis is complicated to perform. Alternative materials to 
dendrimers, hyperbranched polymers, have similar properties, but they can be obtained in an 
easy one-pot synthesis method. They are polymers with a densely branched structure and a 
large number of end groups. However, hyperbranched polymers differ from dendrimers which 
have completely branched star-like topologies because they have imperfectly branched or 
irregular structures. Hyperbranched polymers can be characterized by degree of branching 
(DB). DB represents the percentage of dendritic and terminal monomers among the total 
monomers in the polymer and can be calculated according to the following equation: 
 
 =  +  +  +  
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where D, T and L are the fractions of dendritic, terminal and linear units incorporated in a 
hyperbranched polymer. The common values reported for DB are in the range of 0.4 to 0.8.[8] 
For perfectly branched dendrimers the DB is equal to 1.  
High degree of branching together with other unique properties like globular architecture, well 
defined molecular weight, and high number of terminal groups make dendritic polymers 
promising materials for drug delivery.[9] Recent progress has been made in the application of 
dendrimers as an appropriate host for guest molecules, either in the interior or on the periphery 
of the dendrimers, as a carrier in transdermal[10] and oral[11] delivery of drugs or as a targeting 
agent.[12] 
Poly(amido amine) (PAMAM) and poly(propylene imine) (PPI) dendrimers are the most 
widely investigated polymers for the synthesis of dendrimers. Due to differences in the 
chemical composition, the properties of dendrimers, such as solvent penetration and guest 
doping, are different from each other in dependence upon a different chemical structure. The 
interest in physicochemical properties of PPI dendrimers gained attention to use 
hyperbranched poly(ethylene imine) (PEI),[13] which have a shorter alkyl spacer than PPI. 
Poly(ethylene imine) is one of the commercially available cationic polyamines which have 
been widely used as an efficient drug carrier or a gene delivery system.[14] Among the non-
viral gene vectors, PEI shows outstanding gene complexation efficiency and great endosome 
escape activity, however, it can destabilize the cell membrane, which will cause cytotoxicity. 
Transfection efficiency and toxicity of cationic polymers are highly dependent on molecular 
weight and structure. Low molecular weight PEI has low cytotoxicity, but its transfection 
efficiency is very poor. In contrast, high molecular weight PEI shows a high transfection 
efficiency but it also induces higher cytotoxicity.[15] There have been several approaches to 
decrease the toxicity of hyperbranched PEI, while maintaining the merits of high transfection 
efficiency by combining PEI with biodegradable polymer to make an ideal non-viral vector, 
for example through PEGylation[16] or decorating with an oligosaccharide architecture.[14] 
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1.1. Glycopolymers 
Glycopolymers are natural or synthetic carbohydrate-containing polymers, as well as 
synthetically modified natural sugar-based polymers. With functions similar to those of natural 
carbohydrates, synthetic glycopolymers are fabricated with specific pendant saccharide 
moieties. Sugars are a large group of organic compounds, which are essential components of 
living organisms, serving for the source of energy and as structural components. Beside their 
use as key chemical raw materials, they have been recognized as crucial components of a wide 
variety of complex biological processes. Terminal sugar units of natural glycoconjugates play 
a decisive role in molecular recognition of multivalent carbohydrate–protein interactions and 
are involved in a large variety of intercellular processes including, for example, targeting 
drugs, cell growth regulation, cell differentiation, cell–cell interactions, or cancer cell 
aggregation.[17, 18] 
 
Most commonly used synthetic polymers for design and synthesis of dendrimers, such as 
polyamine dendrons and dendrimers have hydrophobic surfaces and poor solubility. Therefore, 
a chemical modification of the polymer surfaces by carbohydrates is an attractive way to 
increase the solubility and decrease the cytotoxicity of the polymer. Decoration of dendritic 
polymers with carbohydrates was developed as an alternative way to PEGylation, which is so 
far the dominating choice for establishing highly biocompatible delivery systems and 
therapeutics for in vitro and in vivo applications.[19] 
 
Dendritic glycopolymers can be characterized by the degree of (oligo-)saccharide 
functionalization (DF) of dendritic polyamine scaffolds (PPI dendrimers and hyperbranched 
PEI) and the terms “open shell” and “dense shell” have been introduced to describe their 
molecular characteristics.[20] The “dense shell” architecture is characterized by conversion of 
the primary amino groups of the dendritic polyamine scaffolds into tertiary amino groups 
bearing two chemically coupled (oligo-)saccharide units (disubstitution).[14, 21] In the “open 
shell” architecture primary amino groups are fully or partially converted into secondary amino 
groups only bearing one chemically attached (oligo-)saccharide unit (monosubstitution).[14]  
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Figure 2: Schematic presentation of PEI dendrimers with different degrees of oligosaccharide 
functionalization. Branching units: L= linear unit; T= terminal unit and D = dendritic unit.[20] 
For the generation of various oligosaccharide substitution degrees, there is an easy one pot 
approach for the synthesis on the PEI surface. Sugar moieties are covalently bound to the 
primary and secondary amines of PEI by reductive amination reaction. HPEI offers primary 
amines (terminal units T) and secondary amines (linear units L) that can be converted to the 
tertiary amines. Different architectures could be obtained with regards to their structure and 
the degree of substitution as presented in Figure 2. All the structures can be described using 
DF, which is characterized by the fact that two (oligo-)saccharide units can be coupled to one 
T unit and one (oligo-)saccharide can be additionally attached to one L unit [DF is presented 
as  n	Mal2×T + L 	%]. 
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(i) Structure A: PEI surface is decorated with a densely organized oligosaccharide shell. It is 
characterized with preferred D units over the PEI macromolecule with nearly all T units and 
also most L units converted into D units [the T unit had to react twice with an (oligo-) 
saccharide]. The synthesis of structure A is based on the use of oligosaccharides excess with 
the corresponding DF in the range between 75 and 95% (Figure 2).  
(ii) Structure B: PEI surface has a lower degree of functionalization and a loose shell. It is 
characterized with preferred L peripheral groups. It has less secondary amines converted to 
tertiary amines, and could be obtained by utilization of low EI:sugar ratio (1:0.5). DF is in the 
range between 32 and 48% (Figure 2). 
(iii) Structure C: PEI surface is characterized with a mixture of T and L units as peripheral 
groups. It shows an open sugar shell with free primary amines in comparison to structure A 
and B. It could be obtained by utilization of EI:sugar ratio (1:0.2). DF of structure C is in the 
range between 16 and 30% (Figure 2).[14] 
 
Dense and open shell dendritic PEI glycopolymers exhibit pH-dependent cationic surface 
charges and charge density over a broad pH range (2 to isoelectric point) tailored by the given 
(oligo-) saccharide architectures. Dense shell architecture has the lowest cationic charge and 
open shell architecture with remaining primary amines possesses larger cationic charge.[20] PEI 
is a weak polyelectrolyte and the higher the degree of chemically coupled oligosaccharide 
units on the PEI surface, the lower the charge density is.[14] Appropriate modifications of 
cationic surface groups of dendritic polymers with sugar moieties can significantly reduce 
their toxicity which is dependent on the number and nature of functional surface groups.[22] 
2. Used proteins 
2.1. Avidin 
Avidin is a 67-kDa glycoprotein found in egg white, which has a strong avidity for biotin, a 
244-Da water-soluble vitamin H.[23] In recent years, the avidin-biotin complex has gained 
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great attention as an extremely versatile, general mediator in a wide variety of bioanalytical 
applications. The reason for interest in the research of this system is the highest known affinity 
(Ka ≈1015 M-1)[24] in nature and consequently high stability of this noncovalent interaction 
between a ligand and a protein which has been widely used as an universal tool, particularly 
for diagnostic purposes.[23]  
 
Figure 3: Structure of avidin. Monomer unit (left) and natural tetramer (right).[24] 
 
Avidin is a tetrameric protein, composed of four subunits of identical amino acid composition 
and sequence, each possessing one biotin binding site. Structure of avidin is presented in 
Figure 3. A binding site which exhibits such a strong affinity to biotin is also expected to 
interact with other molecules with smaller strength or specificity. Avidin is able to bind to a 
variety of different dyes and peptides which have no structural similarity to biotin. One such 
compound for avidin is a dye, 2-(4’-hydroxyazobenzene) benzoic acid (HABA), which 
provides an additional system for studying low-affinity protein–ligand interactions. HABA has 
become very important in avidin-biotin technology since it can be readily used to determine 
the amount and biotin binding activity of avidin in solution.[25] 
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Figure 4: Scheme presenting the ability of HABA to determine biotin binding activity of 
avidin in solution.[26]  
The use of HABA enables a quick estimation of the mole-to-mole ratio of biotin to protein. 
Quantification of the amount of incorporated biotin is based on the change in absorbance 
related to the amount of biotin in the sample. A solution containing the biotinylated protein is 
added to a mixture of HABA and avidin and because of its higher affinity to avidin, biotin 
displaces the HABA from its interaction with avidin. Figure 4 presents the use of HABA for 
the estimation of biotin to protein ratio. 
2.1.1. Streptavidin 
Streptavidin is a 53-kDa protein isolated from the bacterium Streptomyces avidinii. It is 
similar to avidin with respect to its binding affinity toward biotin (Ka ≈1015 M-1).[23] 
Streptavidin also has a high thermostability (Tm of 112°C for biotin-streptavidin) and is 
resistant against extreme pH, denaturing agents, and enzymatic degradation, which are 
important traits for the use under a wide range of experimental conditions.[27] The structure of 
streptavidin, similarly to avidin, consists of four identical subunits, where each subunit has a 
single biotin-binding site. The protein structure is shown in Figure 5. 
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Despite the similarities between avidin and streptavidin in their affinity to biotin and protein 
subunit conformation, they show different behavior in biochemical properties. Avidin is 
highly glycosylated containing terminal N-acetylglucosamine and mannose residues and 
approximately 10% of its mass belongs to carbohydrates,[28] whereas streptavidin contains no 
carbohydrate residues. Additionally, avidin contains twice as many basic amino acids, lysine 
and arginine as streptavidin, which makes it positively charged with an isoelectric point of 
approximately 10, whereas the isoelectric point of streptavidin is in the range of 5-8.[23] 
Moderation in overall charge of streptavidin substantially reduces the amount of nonspecific 
binding due to the ionic interaction with other molecules. Due to these factors, the use of 
streptavidin – biotin system leads to better signal-to-noise ratios in different assays than 
employing an avidin-biotin system.   
 
Figure 5: Structure of Streptavidin. Monomer unit (left), Tetramer unit with biotin 
molecules.[29] 
2.1.2. Neutravidin  
Due to its glycosylation and high pI the utility of avidin is somewhat limited by nonspecific 
interactions. Neutravidin is a 60-kDa deglycosylated form of avidin, which possesses 
enhanced biotin binding specificity. The neutravidin protein does not contain carbohydrates, 
thus lowering the nonspecific binding, relative to avidin, without significantly affecting the 
affinity to biotin.[30] Table 1 presents the comparison between different biotin-binding 
proteins.  
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Table 1. Properties of different biotin-binding proteins.[31]  
Protein Avidin Strepavidin Neutravidin 
Molecular Weight 67 kDa 53 kDa 60 kDa 
Biotin-binding Sites 4 4 4 
Isoelectric Point 10 5-8 6.3 
Specificity to biotin 
binding 
Low High Highest 
 
3.   Molecular recognition of folic acid by folate receptors  
Nowadays, nanomaterials are being tested and used for the improvement and development of 
new technologies in cancer detection, prevention, and treatment. Due to their size and 
possibility for surface functionalization, nanoparticles can be designed to be used as passive or 
active targeting systems with superior tumor specificity compared to the currently used drug 
methods.  
 
Passive targeting takes advantage of the permeability of tumor tissue. Cancer cells grow 
rapidly, what requires rapid vascularization leading to a leaky and defective architecture. Such 
vascular architecture with defects is more permeable to bigger particles than it is in normal 
tissues, and with the lack of lymphatic drainage in the tumor bed the result is the accumulation 
of the drug within cancer cells. This effect is called the enhanced permeability and retention 
effect (EPR) and is illustrated in Figure 6(a). The EPR effect also affects the ability of a cell to 
uptake vital nutrients and oxygen. If a suitable polymer carrier is coupled with a 
chemotherapeutic agent via a degradable linker, then such carriers have the potential of 
increasing the concentration of the chemotherapeutic agent within the tumor tissue. As a result, 
the concentrations of polymer-drug conjugates in tumor tissue can reach levels 10 to 100 times 
higher than the ones resulting from the administration of the free drug. [32] 
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Folate targeted drug delivery has emerged as an alternative therapy for the treatment of many 
cancers and inflammatory diseases. Because of its small molecular size and high binding 
affinity to cell surface folate receptors (FR), folate conjugates gained attention due to the 
ability to deliver a variety of molecular complexes to pathologic cells without causing harm to 
normal tissues.[33] FR are overexpressed on epithelial cancers of the ovary, mammary gland, 
colon, kidney, lung, prostate, thymus and brain.[34, 35]  
 
 
Figure 6: Concept of tumor-targeting nanoparticles. (a) EPR effect. Leaky vasculature in 
tumor cells compared to healthy cells, owing to fenestrations and gaps between endothelial 
cells that result from abnormal angiogenesis. Nanoparticles in circulation can passively 
extravagate through these gaps and enter the tumor interstitium. (b) Molecular targeting. 
Nanoparticles with folate ligands targeted toward folate receptors overexpressed on the 
surface of tumor cells can be used to actively enhance accumulation of the drug at the tumor 
site and can also help to internalize nanoparticles into cells via endocytosis. [36] 
 
12 
 
Folates (vitamin B9) are important one-carbon donors involved in the amino acid metabolism, 
the synthesis of purines and thymidine — essential components of nucleic acids and formation 
of the primary methylating agent, S-adenosylmethionine, involved in synthesis of DNA, 
proteins and lipids.[37] Cell survival and proliferation are dependent on the cell’s ability to 
acquire the vitamin and its deficiency is therefore associated with many diseases, including 
fetal neural tube defects, cardiovascular disease and cancers.[38] 
 
Folates are hydrophilic anionic molecules that do not cross the cellular membrane alone. They 
can enter the cell through two different routes. One way is by the reduced folate carrier (RFC), 
a bidirectional anion-exchange mechanism, which has low affinity to folate. The ubiquitously 
expressed RFC is the major transporter of folates in mammalian cells and tissues, which 
transports folate cofactors from the blood into cells of peripheral tissues. The other possibility 
to enter the cell is by using the FR pathway, which has a high affinity to folate. Such an active 
targeting system using FR and folate conjugates is presented in Figure 6(b). The FR is 
overexpressed on many rapidly dividing cancer cells and not significantly expressed on most 
normal tissues.[39] Once folate conjugates are bound to a cell surface FR, they are transported 
into the cell through a process called receptor-mediated endocytosis by engulfing them within 
a vesicle called the endosome.[40] After membrane invagination and internalization to form an 
endosome, a proton pump lowers the pH inside the endosome. Since the binding of folic acid 
to its receptor is pH dependent, by decreasing the pH it can be anticipated that some of the 
folate conjugates will escape the endosome resulting in drug deposition in the cytoplasm and 
membrane bound FR mostly recycle back to the cell surface, allowing for delivery of 
additional folate-linked drugs into the cell. [33] 
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Figure 7: Folate-mediated delivery of therapeutic agents to cancer cells expressing folate 
receptors. Two types of strategies can be envisioned: a fraction of the drug carrying 
nanoparticle (NP) functionalized with folic acid will traffic into the cancer cells by receptor-
mediated endocytosis (left side of diagram), while the rest will remain on the cell surfaces 
(right side of diagram).[41] 
4.  Biohybrid structures  
Hybrid has been used as a fashionable term in scientific publications during the past years to 
describe a functional unit consisting of two different elements, possessing a mixed character of 
the initial materials. Biohybrid relates to the material containing or being composed of both 
biological and non-biological components. The biological part of the biohybrid could consist 
of cells or bioactive molecules, while the structural part is of non-biological origin. Biohybrid 
materials are currently used as implants or transplants in regenerative medicine or in vitro 
applications such as assays, biosensors or bioreactors.[42, 43] 
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4.1. Conjugation chemistry in biohybrid materials 
The choice of conjugation strategy is initially dictated by a combination of factors including 
the chemical composition of material, size, shape, surface chemistry (the nature of the surface 
ligands and their available functional groups), the type of biological molecule, its size and 
chemical composition, and the utility desired in the final application. The two most widely 
used conjugation methods between the components in biohybrid structures are covalent 
binding (including covalent coupling of biological component to the nanoparticle surface or 
surface ligand) or noncovalent interactions (including electrostatic attraction, adsorption, 
encapsulation and specific secondary interactions).[44] 
4.1.1.   Covalent binding 
The covalent bond is the most common form of the linkage between the atoms in organic 
chemistry and biochemistry. The reaction between two functional groups leads to the 
formation of a covalent bond via sharing electrons between the atoms. Covalent interactions 
are generally categorized as random (modification at multiple sites) or site-specific 
(modification at a single site). Many different types of covalent modifications can be 
performed with the use of reactive functional groups present or introduced (like carboxylic 
acids, aldehydes, ketones, amines, thiols, etc.) on the macromolecules (peptide, proteins, 
carbohydrate, nucleic acids etc.). Covalent chemistry also commonly involves the use of 
activation agents that function as a molecular bridge between the macromolecule and the 
biological entity.  
4.1.2.   Non covalent interactions  
The simplest non covalent bioconjugation approach is electrostatic interaction, in which the 
attraction between oppositely charged species causes the electrostatic immobilization of small 
molecules or biomolecules. This concept is rather intuitive, nevertheless, its implementation 
shows several complications at the nanoscale since electrostatic effects are amplified, and 
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other factors such as ionic strength, the concentration of reagents, and the type and magnitude 
of charge are significant in obtaining the desired conjugates. Other noncovalent chemistries 
use encapsulation, hydrophobic−hydrophobic or host−guest interactions etc. Specific 
secondary interactions between functional groups bound to the surface of a particle are another 
class of noncovalent interactions. This group is represented by e.g. biotin-avidin interaction, β-
cyclodextrin-adamantane, concanavalin A – sugars, which will be described in detail below.  
4.1.2.1.  β-Cyclodextrin-adamantane host−guest interactions 
Supramolecular host-guest chemistry describes the formation of molecular complexes 
composed of small molecules (guests) noncovalently bound to larger molecules (hosts) in a 
unique structural relationship. 
 
Figure 8: Schematic of adamantane and β-cyclodextrin inclusion complex formation.[45] 
 
Cyclodextrins are naturally occurring water-soluble cyclic oligosaccharides formed by 
monomers of D-glucopyranose bound together by means of α-1,4-glucosidic linkages and 
closed in a ring to form a hollow structure of a truncated cone. The three dimensional structure 
forces the hydroxyl groups on the outer edges, whereas the internal cavity is highly 
hydrophobic and has the ability to form inclusion complexes with a variety of organic and 
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inorganic substrates. The ability of cyclodextrins to include hydrophobic molecules in order to 
increase their solubility in water has led to a variety of applications in the field of 
pharmaceutics.[46] Among many hydrophobic or amphiphilic molecules studied as guests of β-
cyclodextrin internal cavity, special attention has been paid to adamantyl moiety because it 
perfectly fits into the β-cyclodextrin cavity. Adamantane is theoretically formed by four 
cyclohexanes, achieving a strain free and highly symmetrical stable structure. It has a 
spherical group which perfectly matches the cavity of β-cyclodextrin, forming an inclusion 
complex with high values of the association equilibrium constant, typically in the range of 
104–105 M−1.[47] A scheme of adamantane and β-cyclodextrin inclusion complexes formation is 
shown in Figure 8. Due to their high stability, complexes of β-cyclodextrin with adamantane 
found numerous important applications in supramolecular chemistry by combining linear or 
branched polymers bearing cyclodextrin structures and linear polymers bearing adamantyl 
groups to build polymeric systems[48] and in biomedical applications, such as hydrogels[49] or 
surface-mediated gene delivery systems.[45] 
4.1.2.2.  Concanavalin A – sugars 
Lectins are proteins representing a class of carbohydrate binding agents, which are primarily 
extracted from plants and show binding specificity to certain sugar moieties. 
Concanavalin A (Con A) is a saccharide-binding lectin originally extracted from the jack bean, 
which shows reversible strong affinity for sugars, glycoproteins, and glycolipids, containing 
internal and non-reducing terminal α-D-mannosyl and α-D-glucosyl groups. Con A is a 
tetramer consisting of four identical subunits that bind with moderate affinity (Kd≈120-500 
μM) to α-anomers of D-mannose and D-glucose. To depict its binding activity, the protein 
requires metal ions. In the native state of Con A, one molecule binds two metal atoms: Ca2+ 
and Mn2+. The binding sites for the sugar are located adjacent to the metal atoms. In the active 
state of Con A, four subunits are combined together to form a functional aggregate with four 
binding sites. When sugar expressing units are present on the cell surface, Con A binds with 
high avidity due to the multivalent interactions.[50] Such specific interactions with particular 
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sugars made the Con A capable to use as part of a specific cell recognition process or stimuli 
responsive material for the delivery of insulin.[51] 
4.1.2.3.  Biotin – avidin chemistry 
The avidin−biotin complex represents one of the strongest known noncovalent interactions 
with an association constant (Ka) of 1015 M−1. Avidin, as described previously in chapter 2.1, 
is a glycoprotein which comprises a tetrameric subunit structure, with each subunit capable of 
binding one biotin molecule. Biotin is a water-soluble organic compound, also known as 
vitamin B7 or vitamin H. It acts as an essential coenzyme for several carboxylase enzymes, 
which control the metabolism of fatty acids, amino acids, and glucose and are also thought to 
be involved in transcriptional gene expression and stability.[52] 
 
There is a variety of biotin derivatives that make biotinylation of nanoparticles and biological 
molecules rather easy. There are also a great number of commercially available products 
containing biotin which are intended to “biotinylate” their target cognate group on biologicals, 
particularly proteins and antibodies, along with the nanoparticle. There are two principle 
methods of bioconjugation using biotin−avidin chemistry, which are illustrated in Figure 9. 
The first method involves an avidin-functionalized nanoparticle being mixed with a 
biotinylated biomolecule. Using this method, avidin will probably obscure one or more 
available biotin binding sites during initial modification of the particle. The final nanoparticle 
functionalized with the avidin will probably display many different orientations and an 
average range of available binding sites. In the second method, which is often used in 
conjunction with polymer-based nanoparticles, the monomer unit is biotinylated prior to its 
incorporation into the particle. In such an approach, typically the biomolecule is also 
biotinylated, and the two are cross-linked via an avidin intermediary. It is also possible to add 
a PEG, or another extended linker, inserted adjacent to the biotin group to facilitate binding 
within avidin's relatively deep binding pocket.[53] 
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Figure 9: Possible methods of bioconjugation using biotin-avidin chemistry. 1 and 3 – 
modification through biotinylation of functional groups. 2 – direct modification of avidin.[26]   
 
Avidin-biotin technology has been used in many applications, such as delivery of diagnostic 
agents,[23] in molecular biorecognition,[54] or cell imaging.[55] The use of the high-affinity 
nature of avidin is also a versatile approach to target nanoparticles into the tumor tissue. 
Recently, this technology has been frequently applied for drug targeting.[56, 57] The three-step 
method using avidin–biotin technology that is used in human imaging and cancer therapy is 
based on the following steps: (i) administration of biotinylated targeting ligands, (ii) 
administration of avidin and (iii) administration of biotinylated drug or drug-loaded carrier.[58] 
 
Such avidin – biotin systems were used by Ennen et al. in order to synthesize biohybrid 
structures consisting of biotinylated glycodendrimers and proteins for future biomedical 
applications.[53] Poly(propylene imine) dendrimers of the 4th generation modified with an 
oligosaccharide shell and possessing biotin ligands with varied spacer lengths and different 
biotinylation degrees were investigated in the frame of interaction with avidin. It was shown 
that the coupling of the biotinylated glycodendrimers to avidin as a central and bridging 
building block leads to nanometer-sized biohybrid structures with potential functionalities. 
Fabrication of such biohybrid structures is tailored by inter- and intramolecular association 
and dissociation steps until final sizes of the supramolecular structures are achieved. It was 
determined that by using different molar interaction ratios between mono-, bi- and tetravalent 
biotinylated glycodendrimers and avidin, different nanometer-sized biohybrid structures can 
be fabricated. It was shown that size dimension of the biohybrid structures can be controlled 
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mainly by the degree of biotinylation and the defined ligand–receptor stoichiometries. 
Furthermore, the longer biotin-PEG12-COOH ligand was proved to be the more effective in the 
bioconjugation strategy than the shorter 6-(N-biotinylamino)caproic acid ligand for 
establishing the biohybrid structures with avidin as a central unit. In another study it was 
investigated to what extent the size and flexibility of the dendritic scaffold, the degree of 
biotinylation of the biotinylated glycopolymer, the ligand−receptor stoichiometry of avidin to 
biotinylated glycopolymer, and the length and/or chemical structure of the biotin ligand 
impact the properties of the formed biohybrid structures composed of avidin and biotinylated 
glycopolymer.[59] Such nanostructures were investigated with regard to their potential 
biomedical applications as a multifunctional platform with short- and long-term stability 
properties. This research showed the opportunity to design more complex nanostructures 
based on sequential polyassociation reactions with at least two different biotinylated 
molecules and/or the use of at least two different conjugation strategies (e.g. avidin−biotin and 
adamantane-β-cyclodextrin) for future biomedical and biotechnological applications in the 
field of fabrication of larger and uniformly nanometer-sized biohybrid structures with specific 
biological functions.  
The challenge for such kinds of systems is a complete conversion of both glycopolymer and 
avidin. The future task would be to establish a glycopolymer with higher biotinylization 
degree. The optimal number of biotin ligands should be between 5 and 8 in order to achieve 
the full conversion of both glycopolymer-biotin system and avidin. The other open question 
concerns if such materials can be additionally functionalized through further non-covalent 
interactions. It was proved that avidin still possesses free binding pockets in the formed 
biohybrid structures that could be possibly used for the other functionalization through the 
biotin-PEG chain. The other possibility for the future is establishing avidin-biotin-PEG-
glycopolymer precomplex for further functionalization of free biotin ligands of the 
glycopolymers through another biotin acceptor.  
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5. Methods  
5.1. Dynamic light scattering 
Light scattering occurs on polarizable solid and liquid particles (or molecules) illuminated 
with a light beam because of the differences in the dielectric properties of the material and the 
surrounding media. Colloidal sized particles in a liquid undergo random ("Brownian") motion 
owing to multiple collisions with the thermally driven molecules of the liquid and causing 
short-term fluctuations in the measured intensity of the scattered light that carry the 
information about the diffusion coefficient of the particles.[60] According to the Stokes-
Einstein theory of Brownian motion, movement of the particle is dependent on the suspending 
fluid viscosity, temperature, electrical charge, electrical mobility and the size of the particle, as 
seen in the following equations: 
 = 6 
 
 =   
where D is diffusion constant, q is electrical charge, μq is electrical mobility of the charged 
particle, kB is Boltzmann’s constant, T is absolute temperature, η is viscosity, and r is the 
radius of the spherical particle.[61] Using Stokes-Einstein theory, determination of the particle 
motion in a fluid of known temperature and viscosity can lead to the determination of particle 
size. The rate of the movement is inversely proportional to the particle size in solution (the 
smaller the particles are, the faster their motion or diffusion), and is analyzed by measurement 
of light intensity fluctuations scattered over the time from the particles when they are 
illuminated with a laser beam. Various terms have been proposed for this phenomenon: photon 
correlation spectroscopy (PCS), dynamic light scattering (DLS), quasi-elastic light scattering 
(QELS) and others. DLS measures the Brownian motion of the particles and relates this 
movement to an equivalent hydrodynamic size. Through application of the autocorrelation 
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function and subsequent calculation of the exponential decay, average particle size can be 
obtained from the time-dependent fluctuations in light intensity.  
5.2. Zeta potential 
Zeta potential measurement is a measure of the electrical charge developed when a solid 
surface is brought into contact with an aqueous solution. Zeta potential is the electrical 
potential at the shear plane of the electric double layer. It depends on the properties of liquid 
as well as on the properties of the surface.  
In the solution free ions tend to rearrange themselves in such a way that a thin region of non-
zero net charge density exists near the interface. The development of a net charge at the 
particle surface affects the distribution of ions in the surrounding interfacial region, resulting 
in an increased concentration of counter ions close to the surface and an electrical double layer 
(EDL) formation around each particle. The EDL consists of two parts, an inner region called 
the Stern layer, in which the ions are strongly bound and an outer region called diffuse layer, 
in which they are mobile. As presented in Figure 10, the stern layer has an approximate one 
ion radius thickness. Counterions experience strong electrostatic forces there and are 
essentially immobilized against the surface. Ions located in the diffuse layer experience a 
weaker electrostatic attraction. Due to the competing electrostatic and thermal forces, 
concentration of ions in the diffuse layer is the highest at the surface and decreases gradually 
with distance until it reaches equilibrium with the bulk concentration. The thickness of the 
diffuse layer is often characterized by the Debye length λD and it can vary from several 
nanometers to micrometers depending on the concentration and properties of the solution. 
The boundary between the stern and diffuse layer is called shear plane and zeta potential is the 
electrostatic potential at the boundary dividing those regions. Depending on the solid surface 
and the solution, zeta potentials values are within a range of −100 mV to +100 mV for most 
solid– liquid interfaces in aqueous solutions.[62] 
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Figure 10: Schematic representation of the electric double layer.[62] 
5.3. Alamar Blue Assay 
The Alamar Blue test is an assay which has been widely used in studies on cell viability and 
cytotoxicity in a range of biological and environmental applications. It can be used to assess 
different types of human and animal cell lines, as well as various bacteria, yeast and fungus 
species. The Alamar Blue reagent is a water-soluble dye that is used for quantifying in vitro 
viability of cells. It is very stable, permeable through cell membranes and nontoxic to the cells 
which allows for continuous monitoring of cultures. The active ingredient of Alamar Blue is 
resazurin, also known as diazo-resorcinol, azoresorcin, resazoin or resazurine. It is a blue non-
fluorescent dye which changes to highly fluorescent pink-colored resorufin upon reduction of 
the oxidized form. The change of the structure is presented in Figure 11. Resazurin can be 
reduced by NADPH, FADH, FMNH, NADH, as well as the cytochromes and other enzymes 
(such as the diaphorases, dihydrolipoamine dehydrogenase, NAD(P)H:quinone oxidoreductase 
and flavin reductase) located in the cytoplasm and mitochondria. This change from oxidized to 
reduced state allows for quantitative (colorimetric and/or fluorometric readings) or qualitative 
measurement (visible change in color indicating presence or absence of viable cells). 
Spectrophotometric absorbance is measured at two wavelengths (570 and 600 nm or 540 and 
630 nm) and fluorescence signals are measured at an excitation wavelength at 530–560 nm 
and an emission wavelength at 590 nm.[63] 
23 
 
 
 
Figure 11: Alamar Blue assay principle. Reduction of resazurin converts the essentially 
nonfluorescent dye to the highly pink fluorescent resorufin 
5.4. Flow cytometry 
Flow cytometry is an analytical technique which provides rapid analysis of multiple 
characteristics of single cells. It measures the optical and fluorescence characteristics of single 
cells (or any other particle, including nuclei, microorganisms, chromosome preparations, bone 
marrow, urine, and solid tissues). The information obtained is both qualitative and quantitative 
and it includes physical properties such as size (represented by forward angle light scatter), 
internal complexity (represented by right-angle scatter), DNA or RNA content, and a wide 
range of membrane-bound and intracellular proteins. Typically fluorescent dyes are bound or 
intercalated with different cellular components such as DNA or RNA, or antibodies 
conjugated to fluorescent dyes that can bind specific proteins to cell membranes or inside the 
cells.[64] Inside a flow cytometer, labeled cells pass through a light source, causing the 
excitation of the fluorescent molecules to a higher energy state. Upon returning to their initial 
states, light is emitted in all directions and collected via optics that direct the light to a series 
of filters and dichroic mirrors that isolate particular wavelength bands. Using multiple 
fluorochromes with similar excitation wavelengths and different emission wavelengths it is 
possible to measure several cell properties simultaneously. The resulting information is 
usually displayed in histogram or two dimensional dot-plot graphs.  
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Figure 12: Principle of a flow cytometer. A single cell suspension is hydrodynamically 
focused with fluid stream to intersect a light source. Signals are collected by a forward angle 
light scatter detector, a sidescatter detector (1), and multiple fluorescence emission detectors 
(2–4). The signals are amplified and converted to digital signal and displayed on the 
computer.[64] 
 
Flow cytometer consists of three main systems: fluidics, optics and electronics. Fluidic system 
permits the hydrodynamic focusing, which means that it is drawing the suspension of cells 
into a stream created by a surrounding sheath of isotonic fluid that creates laminar flow, 
allowing the cells to pass one by one across the laser beam for individual analysis. In the 
optics system, a beam of monochromatic light intersects the cells and it is the starting point of 
fluorescence emissions and light scattering (forward scatter and side scatter) which is 
measured at different angles. Nowadays, diode lasers or lasers are used for the excitation light 
sources. Optical lenses are also used to control illumination point geometry with very good 
light focalization. Side scatter and fluorescent lights are filtered by dichroic mirrors and 
emission filters into an emission optical system which directs lights at different wavelengths 
towards appropriate detectors. In the electronics system, the light signals are detected by 
photomultiplier tubes and digitized for computer analysis. Flow cytometers can be also 
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equipped with cell sorters, which has the possibility of isolating subpopulations of cells of 
interest with high recovery and high degree of purity from heterogeneous cell mixtures based 
on light scattering and fluorescent characteristics.[65] Figure 12 presents the schematic diagram 
of the fluidic and optical components of a flow cytometer. 
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II. Aim of the thesis  
The activity of pharmaceuticals against certain diseases is mostly not based on their ability to 
accumulate selectively in the pathological organ, tissue or cell. Usually, the pharmaceutical 
agents are rather evenly distributed within large areas of the body, independently from the 
route of administration. In order to reach the site of action, the drug has to cross many 
biological barriers, such as other organs, cells and intracellular compartments, where it can be 
inactivated or express undesirable influence on organs and tissues that are not involved in the 
pathological processes. As a result, the drug has to be administered in large quantities to 
achieve a required therapeutic concentration in a certain body compartment, the great part of 
which is wasted in normal tissues and can cause many negative side effects.[66] 
Drug targeting can bring a solution to all these problems. It is the ability of the drug to 
accumulate in the target organ or tissue selectively and quantitatively, independent of the site 
and methods of its administration.[67] In the ideal case, the local concentration of the drug at 
the disease site should be high, while its concentration in the other non-target organs and 
tissues should be below certain minimal level to prevent any negative side-reactions. 
The aim of this thesis is the fabrication and characterization of the novel, tailor-made 
nanocarrier with the defined size and structure for the selective targeting to the tumor tissues. 
The biohybrid structures (BHS) based on streptavidin and pentavalent biotinylated dendritic 
glycopolymer will be fabricated through non-covalent streptavidin-biotin conjugation and 
further functionalized with the folic acid for the specific targeting to tumor cells. The system is 
schematically presented in Figure 13. It will be investigated if it is possible to further 
functionalize such BHS through additional streptavidin-biotin interaction and if such system 
could be applied in biomedical applications as targeting carrier. It will be determined if there 
are accessible functional units at the surface of BHS that could be used for further 
functionalizations.  
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The cytotoxicity of the BHS will be investigated to assess the biocompatibility of the system. 
The comparison between the molecular uptake in normal and cancer cells will be made in 
order to prove the ability of the system for the selective targeting to the tumor cells. The 
influence of the type of protein, amount of folic acid and the length of the PEG-chain / spacer 
will be evaluated, just as the impact of purification strategies to show the influence of the folic 
acid ligand as targeting function towards folate receptor expressing cancer cells. Cell uptake 
mechanism will be also investigated. Furthermore, the physical properties of the BHS will be 
analyzed by dynamic light scattering and zeta potential measurements. Additionally, the long 
term stability properties of the structures together with the stability towards excess biotin 
ligands will be determined. 
 
Figure 13: Schematic presentation of the biohybrid structure consisted of biotinylated 
glycopolymer and streptavidin and modified with folic acid fabricated in the frame of the 
thesis. 
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III. Results and discussion 
1. Introduction to biohybrid structures 
Biohybrid structures (BHS) fabricated in the frame of this thesis consists of dendritic 
glycopolymers which are conjugated through biotin – streptavidin interaction and further 
functionalized with chains terminated with the folic acid.  
 
Figure 14: Synthesis scheme of the biohybrid structures modified with the folic acid.  
 
The central unit of the system is hyperbranched poly(ethylene imine) (PEI) with the average 
molecular weight of 25000 g∙mol-1, which was functionalized through the poly(ethylene 
glycol)12-biotin (PEG12-biotin) ligand. The fabricated structure possesses five PEG12-biotin 
ligands. Biotinylization of the polymer enabled further formation of BHS by conjugation 
through one of the strongest known non-covalent interaction of biotin with streptavidin (SA). 
In order to decrease the cytotoxicity of PEI and decrease the surface charge of the structure, 
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the polymer was glycosylated using maltose and the glycopolymer with the dense-shell 
architecture was obtained. The modification of PEI with maltose and PEG12-biotin was 
performed by Johannes Fingernagel, member of the working group of Dr Appelhans. Total 
molecular weight of dendritic glycopolymer calculated by elemental analysis was 74 300 
g∙mol-1.  
Table 2. Overview of the components and biohybrid structures 
Systematic description Abbreviation 
PEI25k-(PEG12Biotin)5-Maltose  PEI-biotin 
Streptavidin SA 
PEI25k-(PEG12Biotin)5-Maltose + Streptavidin BHS 
Biotin-PEG-Folic acid Folate 
Biotin-PEG-COOH Biotin-PEG 
PEI25k-(PEG12Biotin)5-Maltose + Streptavidin 
+ Biotin-PEG-Folic acid2k 
BHS-Folate2k 
PEI25k-(PEG12Biotin)5-Maltose + Streptavidin 
+ Biotin-PEG-Folic acid5k 
BHS-Folate5k 
PEI25k-(PEG12Biotin)5-Maltose + Streptavidin 
+ Biotin-PEG-COOH2k 
BHS-Biotin-PEG2k 
PEI25k-(PEG12Biotin)5-Maltose + Streptavidin 
+ Biotin-PEG-COOH5k 
BHS-Biotin-PEG5k 
 
BHS composed of modified PEI-biotin and SA were further functionalized with the biotin-
PEG-folic acid (folate) chain in order to increase the specific targeting to the cancer cells or 
with the biotin-PEG-COOH (biotin-PEG) chain as a reference. Two different chain lengths 
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were used: 2000 g∙mol-1 and 5000 g∙mol-1 and structures with different ratios of PEI-
biotin/SA/Folate were tested. The scheme of the BHS formation and modification with the 
folic acid is presented in Figure 14 and all the fabricated BHS are listed in Table 2 together 
with the introduced abbreviations that will be further used in the thesis. 
2. Characterization of the BHS size by DLS 
2.1. Formation of the BHS 
In order to prove the formation of BHS, the measurements of size were performed with the use 
of DLS technique. In Figure 15, the sizes of hydrodynamic diameters of PEI-biotin, SA and 
the BHS in the molar ratio of SA/PEI-biotin 1/1 are presented.  
 
Figure 15: Size of the single components and the biohybrid structures 
 
Solution containing only PEI-biotin was measured having the particles with the diameter of 
around 10-12 nm. Particles of the protein have the average diameter of 5-6 nm. Measurement 
of the BHS consisting of these 2 components clearly showed the shift in the size up to 38 nm 
what proves the formation of the structures via biotin – streptavidin interaction through the 
polyassociation reaction.  
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2.2. Comparison between BHS fabricated with different ratios of 
SA/PEI-biotin 
The next step was the comparison of the size of the structures fabricated with different molar 
ratios of SA/PEI-biotin. Structures with the molar ratios 1/0.5, 1/1 and 1/2 were prepared and 
the results of DLS measurement are presented in Figure 16. 
 
Figure 16: Comparison of the BHS size fabricated from different ratios of SA/PEI-biotin 
 
Using streptavidin–biotin conjugation as the deciding non-covalent interaction step, different 
nanometer-sized biohybrid structures can be established and size can be controlled by using 
different molar ratios between SA and PEI-biotin. Structures formed from the mixture of SA 
and PEI-biotin in the ratio 1/1 have the highest average diameter compared with the structures 
formed from the ratio 1/0.5 or 1/2. Table 3 presents the comparison between molar ratio and 
ligand stoichiometry of different BHS. In the previous study of Dr Appelhans group, it was 
established that SA has in average 3.6 free binding pockets per molecule and PEI is modified 
with 5 PEG12-biotin ligands. In Table 3 it can be seen that depending on the stoichiometry of 
the components, structures with the excess of free binding pockets or the excess of biotin will 
be obtained.  
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Table 3. Comparison between molar ratio and ligand stoichiometry of BHS with different 
SA/PEI-biotin ratio. Mass concentration is given for the structures with the molar mass of SA 
2.5 g∙mol-1 and the corresponding PEI-biotin concentration. 
Molar ratio of 
SA/PEI-biotin 
Average 
hydrodynamic 
diameter, nm 
Number of binding 
units 
Ligand 
stoichiometry 
Mass 
concentration, 
mg∙ml-1 SA 
PEI-
biotin 
SA 
PEI-
biotin 
1/0.5 
1/1 
1/2 
22 
38 
29 
3.6 
3.6 
3.6 
2.5 
5 
7.5 
1 
1 
1 
0.69 
1.39 
2.08 
0.31 
0.40 
0.59 
 
In order to fabricate the structures with the optimal sizes, the ratio of the number of free 
binding pockets to biotin molecules should be close to one. As it can be seen in the example of 
1/0.5 molar ratio, ligand stoichiometry below 1/1 dramatically decreased the size of the 
structure up to 22 nm. When the SA/PEI-biotin molar ratio is increased up to 1/2, the number 
of biotin molecules is doubled compared with the free binding pockets of the protein. 
Furthermore, decrease in the molar ratio from 1/1 to 1/0.5 caused a small decrease in the mass 
concentration of the structures. Doubling the amount of PEI-biotin, the mass concentration 
raised almost 50% compared with the structures of the ratio 1/1. The most optimal results were 
obtained for the SA/PEI-biotin ratio 1/1 and only this ratio will be used for the further 
modifications of the structures.  
2.3. Size of non-modified and modified BHS 
In the next step, the BHS were modified with folate and the difference between the size of 
non-modified and modified BHS was tested. Folate ligands were added in the ratio PEI-
biotin/SA/Folate 1/1/6. In Figure 17 the influence of modification on the BHS size is 
presented on the example of BHS modified with Folate5k. After addition of folate there is no 
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measurable size change or a change is very minimal (around 1 nm). The folate molecules are 
comparatively small and there is no clear size change after the modification of BHS.  
 
 
Figure 17: Comparison of the size of non-modified and modified with folate BHS 
 
Important question here is how many folate ligands are able to bind to SA and how many free 
binding pockets of the protein are accessible on the surface of the structure for further 
modifications. In order to investigate it, the theoretical calculation how many available 
binding pockets are accessible on the surface and how many are inside the structure will be 
presented here. AF4 measurements obtained by Dr. Appelhans working group showed that 
BHS fabricated from SA/PEI-biotin molar ratio 1/1 have the hydrodynamic diameter of 49 nm 
and the molar mass of 1 146 000 g∙mol-1. Total number of SA molecules in the fabricated BHS 
is given by: 
  =  !	"#$%&'()'* + !+ =
1146000 g ∙ mol%3 
	74300 g ∙ mol%3 + 55000 g ∙ mol%3 = 8.86 
Each SA molecule possesses in average 3.6 binding sites which means that the total number of 
SA binding pockets in BHS is equal to: 
 9:;:< =>?@AB = 8.86 ∗ 3.6 = 31.9 
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In the previous study of Dr Appelhans’s group it was estimated that 50% of the avidin’s 
binding pockets are available and for SA I will assume similar behavior: 
 E@@ 9:;:< =>?@AB = 50% ∗ 31.9 = 15.95 
In the next step the surface area of the BHS where the SA pockets are available to bind to 
other biotinylated molecules has to be estimated. In this calculation it will be assumed that the 
other molecules are able to bind to SA pockets which are available up to 5 nm depth from the 
surface. Total volume of the structure is equal to (R is diameter of the sphere): 
F)()GH = 43  I
J
2K
L
= 43  I
49 M
2 K
L
= 61601 ML 
The inner volume of the structure is given by: 
F'**NO = 43 J
L = 43  I
49 M − 2 ∗ 5 M 
2 K
L
= 31059 ML 
The volume of the surface shell with the depth of 5 nm is equal: 
FQRNHH = F)()GH − F'**NO = 30542 ML  
The ratio of the surface shell volume to the total volume is: 
FQRNHH
F)()GH =
30542 ML 
61601 ML = 0.496 
The number of available binding pockets in the surface shell can be calculated by: 
FQRNHH
F)()GH ∗  E@@ 9:;:< =>?@AB = 0.496 ∗ 15.95 = 7.9 
This estimation showed that on the surface shell of the BHS there are in average 7.9 free 
binding pockets that could be possibly used for further functionalization with folate or other 
kinds of biotinylated molecules.  
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2.4. Stability of non-modified and modified BHS 
2.4.1. Long term stability of the structures 
Important question in the study of such BHS with regard to potential future biomedical 
applications are the long term stability properties. The measurement of the size of BHS with 
different SA/PEI-biotin ratio, namely 1/0.5, 1/1 and 1/2 was performed during the period of 
one month. The samples were stored at 7 °C. In Figure 18, the measurement of the 
hydrodynamic size of the BHS consisted of SA/PEI-biotin 1/1 over the time is presented. For 
the other two SA/PEI-biotin ratios the results looked identical and are presented in appendix 
on the page 84. The size of the structures remained the same over the period of 27 days, which 
means that after the formation process BHS are stable and the non-covalent interaction 
between the SA and biotin remains after the long time. Furthermore, there was no additional 
and uncontrolled aggregation process over the time.  
 
Figure 18: Long term stability study of the non-modified BHS consisted of SA/PEI-biotin 1/1. 
 
In the next step, the long term stability properties of the BHS modified with folate were tested. 
The measurement was performed for the structures with Folate2k and Folate5k. The impact of 
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purification was additionally investigated. For all the structures the results looked identical 
and the example is shown in Figure 19. The graphs for the rest of the structures are shown in 
appendix on the pages 85 and 86. After addition of folate, there is a very small shift in the size 
which is stable over the period of one month. It means that additional biotin-streptavidin 
conjugation added to the system did not cause disaggregation of BHS and the initial biotin-
streptavidin binding was not broken.  
 
Figure 19: Long term stability study of the purified BHS modified with Folate5k. 
 
2.4.2. Stability against the excess of biotin  
In the next step, the stability of the BHS against free biotin molecules was tested. The aim of 
this investigation was to check if addition of free biotin to the system after the fabrication of 
BHS will cause disassembling of the structures. In the first step BHS with the PEI-biotin/SA 
ratio of 1/1 were produced and after 24 hours free biotin molecules were added to the system 
in the desired molar ratios. Figure 20 presents the DLS results of the BHS with different 
amounts of biotin. 
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Figure 20: Size of the structures with additional biotin molecules. B = Biotin 
After addition of free biotin molecules to the BHS, there is an increase in the sizes of BHS. It 
means that the rearrangement of BHS takes place. Very small biotin molecules can go deep 
inside the structures and do not face sterical problems to fit inside the binding pockets. There 
is no decrease in the size of the structures which means that no degradation of the structures 
takes place.  
 
Figure 21: Size of the structures with additional biotin-PEG molecules. BPEG = Biotin-PEG. 
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In the next step, the stability of BHS against biotin-PEG12-COOH (biotin-PEG12) molecules 
was tested. Similarly as for the experiments with free biotin, BHS with the PEI-biotin/SA ratio 
of 1/1 were produced and after 24 hours free biotin-PEG12 molecules were added to the system 
in the desired molar ratios. Figure 21 presents the DLS results obtained for those structures. In 
the case of adding free biotin-PEG12, there is a small decrease in the size of the structures 
compared with the non-modified BHS. The use of PEG spacer caused the rearrangement to the 
smaller particles, but no degradation to the initial components. It can be suggested that 
compared with free biotin, biotin-PEG12 is a bigger molecule which does not penetrate inside 
the structure. The chain may backfold to the BHS, compress its size and increase the density. 
Biotin-PEG12 can also cause different shielding behavior of BHS. It can have an influence on 
the Stern-layer of the structure by allowing less water to go through the BHS what cause the 
decrease in the measured size value (which is directly correlated to the diffusion coefficient).   
3. Characterization of BHS by zeta potential  
Surface characteristics of the nanocarriers can significantly influence their interaction with the 
cell membrane and hence their internalization pathways. A cell membrane is anionic because 
of the anionic head group of phospholipids and the presence of carbohydrates such as sialic 
acid.[68] Cationic carriers advantageously bind to anionic functional groups on a cell surface 
and translocate across the plasma membrane inside the cell.[69] Neutral and negatively charged 
nanoparticles are expected to be less efficiently adsorbed and taken up by negatively charged 
cell membrane.[69] In order to check the surface charge of the BHS, zeta potential 
measurements were performed. Similar results were obtained for the BHS modified with 
Folate2k and Folate5k. Samples result for BHS modified with Folate2k is presented in Figure 
22. The dependency obtained for BHS modified with Folate5k is presented in appendix, on the 
page 86. Isoelectric point of the structure is at the pH=8.78 and at neutral pH the zeta potential 
is positive. It suggests that fabricated BHS are slightly cationic and the internalization by the 
cell should be favorable.  
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Figure 22: Zeta potential measurement of BHS modified with Folate2k. 
 
4. Cell viability  
Prior to evaluating the selectivity of BHS for targeting to cells, the biocompatibility of the 
structures was proved using the AlamarBlue proliferation assay. In this study, two different 
cell lines were used, the Human Cervix Carcinoma cells (SBC-2, derivative of HELA), 
expressing folate receptor (FR +ve) and the Human Embryonic Kidney 293 cells (HEK293) 
which do not overexpress folate receptor (FR -ve). PEI-biotin, non-modified BHS and BHS 
modified with folate or biotin-PEG were individually evaluated by treating SBC-2 and 
HEK293 cells with different concentrations of the corresponding samples for 24 h. The cells 
were incubated with the mass uptake of 1 μg, 10 μg, 50 μg, 100 μg, 150 μg or 250 μg of the 
desired system.  
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Figure 23: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of PEI-biotin.  
 
Figure 24: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS. 
As shown in Figure 23, PEI-biotin had any adverse effect on the proliferation of HEK293 cells. 
SBC-2 cells demonstrated low cell death level after treating with PEI-biotin, with the drop in 
viability up to 77 % after incubation with the highest concentrations of PEI-biotin. In Figure 
24 cell viabilities after treatment with BHS are presented. Viabilities of HEK293 cells are over 
100% for most of the concentrations which suggests that BHS are biocompatible and cause the 
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cell proliferation. The viabilities of SBC-2 cells, similarly as for PEI-biotin, were reduced up 
to 80% after incubation with the highest concentrations of BHS. For both systems viabilities 
of HEK293 cells were higher compared with SBC-2 cells. Comparison of the viabilities after 
incubation with PEI-biotin and BHS showed that addition of SA to the system significantly 
increased the viability and proliferation of HEK293 cells.  
 
 
Figure 25: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS modified with Folate2k after the purification  
 
Figure 26: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS modified with Folate2k without the purification. 
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Figure 25 and Figure 26 present the cell viabilities after incubation with BHS modified with 
Folate2k, with and without the purification, respectively. In both cases viabilities of HEK293 
cells were over 100%, usually between 120 % and 140 %, which suggests that modified BHS 
are also biocompatible and support the cell proliferation. Comparing with the non-modified 
BHS, addition of Folate2k did not cause any cytotoxic effects to the cells, however the cell 
proliferation was slightly decreased. After incubation with SBC-2 cells, for both purified and 
non-purified systems, the cell viabilities were in the range 90 – 115% which means that 
modified BHS had also any adverse effects on this cell line. Purification of the system 
increased the viability of SBC-2 cells what is especially seen for the high concentrations. 
Viabilities of HEK293 cells were similar for non-purified and purified structures.  
 
 
Figure 27: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS modified with Folate5k after the purification. 
0
20
40
60
80
100
120
140
160
180
control 1 10 50 100 150 250
Ce
ll 
v
ia
bi
lit
y,
 
%
Mass uptake, μg
HEK293 SBC-2
43 
 
 
Figure 28: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS modified with Folate5k without the purification. 
As shown in Figure 27 and Figure 28, for the BHS modified with Folate 5k, irrespectively if 
purified or not, the viabilities of SBC-2 cells were higher than of HEK293. For the purified 
samples there is a strong dependency on the mass uptake, for small mass uptakes the 
viabilities are very high (up to 160%), however for the highly concentrated samples they drop 
up to 80%. The viabilities of SBC-2 cells after incubation with non-purified BHS modified 
with Folate5k are also very high, up to 180%. The possible reason for such high viabilities are 
the stealth properties of SBC-2 cells. The long biotin-PEG spacer interacts with the membrane 
which causes better cell viability. For both, purified and non-purified samples, the viabilities 
of HEK293 cells were in the range of 100-120%.  
Figure 29 and Figure 30 present the results of cytotoxicity test of non-purified BHS modified 
with Biotin-PEG2k and Biotin-PEG5k, respectively. In both cases there are no significant 
differences between the HEK293 and SBC-2 cells and there is no dependency with mass. 
Most of the viability results are in the range of 100 - 120%.  
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Figure 29: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS modified with Biotin-PEG2k. 
 
Figure 30: Viabilities of HEK293 and SBC-2 cells treated for 24 h with different 
concentrations of BHS modified with Biotin-PEG5k. 
In appendix, on the page 87 Figure 58 and Figure 59 present the comparison of the viability 
tests for all the structures of HEK293 and SBC-2 cells, respectively. In general, the results 
showed that none of the systems is toxic under given experimental conditions. Typical 
viability values are around 100% or higher (rarely below 100%). It means that all the 
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structures are biocompatible and do not cause the cell death. The highest viabilities of 
HEK293 cells were reached after incubation with non-modified BHS and BHS modified with 
Folate2k. The highest viabilities of SBC-2 cells were achieved for BHS modified with 
Folate5k. Modification of BHS with folate or Biotin-PEG slightly decreased the viability of 
HEK293 cells and increased the viability of SBC-2 cells. Higher viabilities were reached for 
the BHS modified with Folate2k compared to BHS modified with Folate5k for the HEK293 
cells and for SBC-2 cells it was the opposite. Modification of BHS with folate or Biotin-PEG 
showed that the presence of folic acid can slightly influence the cytotoxicity. For the structures 
modified with 2k chains, viabilities of HEK293 were higher for the BHS modified with the 
folate compared with Biotin-PEG. There was no significant trend observed in SBC-2 cells. 
Viabilities of SBC-2 cells were higher after incubation with BHS modified with Folate5k 
compared with the BHS modified with Biotin-PEG5k and no significant differences were 
observed for HEK293 cells. Purification step did not influence the viabilities of HEK293 cells. 
For the SBC-2 cells, the viabilities were much higher for the non-purified BHS modified with 
Folate5k than for purified. Due to the stealth properties of SBC-2 cells, long biotin-PEG 
spacer can interact with the membrane what causes better cell viability. Free folate molecules 
present in the solution additionally amplify this phenomenon.  
5. Flow cytometry 
In order to demonstrate the ability for selective targeting to the cancer cells, the non-modified 
and modified BHS have been quantitatively evaluated using flow cytometry analysis. Both 
cell lines, SBC-2 cells (FR +ve) and HEK293 cells (FR -ve), were treated only with 200 μg 
mL-1 of FITC-labeled BHS or single components for different incubation times. 
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5.1. Non-modified biohybrid structures based on PEI-biotin/SA and 
PEI-biotin/NA 
Neutravidin (NA) is a derivative of avidin which is non-glycosylated and eliminates the non-
specific binding compared with avidin. At first, BHS based on PEI-biotin and SA or NA were 
tested. The single components of the structures were examined as well. As shown in Figure 31, 
the mean fluorescence intensity (MFI) of both cell lines for SA and NA was very low, 
similarly to the control where cells were incubated only with the cell culture medium. The 
molecular uptake after incubation with PEI-biotin was much higher than with proteins and it 
was higher in HEK293 cells than in SBC-2. After incubation with BHS based on PEI-
biotin/SA, the uptake was few times higher compared with  PEI-biotin and the MFI was 
always two times higher for SBC-2 cells than for HEK293 cells.  
 
Figure 31: Cellular uptake after incubation with non-modified BHS and single components 
for 4h. 
It shows the synergetic effect of BHS formation. The MFI measured for single components 
was very low, however, when they were conjugated it was few times higher. It proves that 
combining the properties of synthetic and biological components we create the biohybrid 
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material with extraordinary and synergetic functions that significantly increases the molecular 
uptake or causes the interaction with the cell membrane. At this step of investigation it is not 
established if the BHS are taken up inside the cell or if they bind to the cellular membrane 
what could also cause high fluorescence intensity values. The MFI values of BHS based on 
PEI-biotin and NA were much lower compared with the structures built from PEI-biotin/SA. 
The value is in the range of MFI for PEI-biotin, which showed that there is no synergetic 
effect when BHS is fabricated from NA. For the further modification with folate, only the 
BHS based on PEI-biotin/SA were chosen.  
 
Figure 32: Cellular uptake BHS based on PEI-biotin/SA after different incubation times 
 
In Figure 32 the time dependency of molecular uptake after incubation with BHS based on 
PEI-biotin/SA is presented. The molecular uptake for both cell lines is increasing with time 
and the MFI was up to two times higher for SBC-2 cells compared with HEK293 for all the 
time points. In Figure 33 and Figure 34 the time comparison for all the components is 
presented for HEK293 and SBC-2 cells, respectively.  
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Figure 33: Cellular uptake of HEK293 cells after different incubation times. 
 
Figure 34: Cellular uptake of SBC-2 cells after different incubation times. 
 
The uptake of HEK293 cells was always the highest for BHS based on PEI-biotin/SA. The 
MFI results for PEI-biotin and PEI-biotin/NA were similar, always around two times smaller 
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than for PEI-biotin/SA. For SBC-2 cells, the molecular uptake after incubation with PEI-
biotin/SA was also the highest. The MFI results for PEI-biotin and PEI-biotin/NA are again 
very similar, however few times lower than PEI-biotin/SA. By comparing Figure 33 and 
Figure 34 it can be seen that the differences between the results for PEI-biotin/SA and the rest 
of the systems is much bigger for SBC-2 cells. Up to two-times higher MFI value in cancer 
cells compared with the normal cells shows that BHS could be promising candidates as 
carriers for selective targeting to tumor cells. Nevertheless, here it is necessary to consider that 
biologically active molecules present in the extracellular medium either bind to membrane 
receptors or the lipid matrix of the membrane, or cross the membrane to act inside the cell. 
Crucial is to know the affinity and binding mechanism of a molecule to the membrane, and 
whether it interacts only with the outer membrane leaflet or whether and how it can translocate 
to the inner leaflet. It is not straightforward to predict whether the nanocarrier translocates 
passively across the membrane and additional experiments on membrane translocation are 
needed to state if the high MFI values obtained for BHS means internalization inside the cell 
or binding to the cell membrane.   
5.2. BHS modified with short folate moieties 
In the next step, the modification of BHS with folate was performed. At first, modification 
was done by adding the short folate spacers with the molar mass of 2000 Da. The experiments 
were prepared with the use of purified and non-purified BHS. Purification step included the 
dialysis of the sample against PBS in order to remove the unbound folate groups from the 
solution. Different amounts of folic acid were used. Structures were prepared with different 
molar ratios of PEI-biotin/SA/Folate, namely 1/1/10, 1/1/8, 1/1/6, 1/1/2 and 1/1/1. 
Furthermore, the cellular uptake after incubation with only Folate2k and the conjugation of 
SA/Folate2k was tested. SA/Folate2k conjugation was prepared without the purification. As 
shown in the chapter 2.3, in the surface shell BHS possess approximately 7.9 free binding 
pockets of SA that could be used for further modifications with biotinylated molecules. It 
means that using the highest molar ratios of PEI-biotin/SA/Folate, the binding pockets of SA 
should be fully saturated with folate molecules. Modifying BHS with small amount of folates, 
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only part of the free pockets should be occupied. Figure 35 shows the results of molecular 
uptake after incubation with different BHS modified with short folate moieties.  
 
Figure 35: Cellular uptake after incubation with BHS modified with Folate2k or single 
components for 4 h. BHS2k = PEI-biotin/SA/Folate2k, non-pur. = non-purified 
The MFI of Folate2k and SA/Folate2k are very low, in the range of the value obtained for the 
control that was incubated only with the cell culture medium. Even though Folate2k and 
SA/Folate2k contained the high number of free folate moieties, there was no uptake by the 
folate receptors expressing cancer cells. The MFI values of BHS modified with folate was 
much higher what proves that combining the properties of single components the material with 
extraordinary and synergetic functions can be fabricated.  
 
The molecular uptake for most of the modified BHS was much higher in SBC-2 cells than in 
HEK293 cells. Comparing the results for the BHS modified with different amounts of folate, 
the highest MFI values were obtained for the PEI-biotin/SA/Folate2k of 1/1/6 and 1/1/2, in 
both cases for the purified samples and the molecular uptake was higher compared with the 
non-modified BHS. Such enhancement in the cellular uptake was presumably due to the 
successful recognition of folic acid present in the system by the folate receptors overexpressed 
on the SBC-2 cells. Figure 36 presents the different cell internalization pathways depending on 
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the kind of cell for the structures with the above mentioned molar ratios of PEI-
biotin/SA/Folate2k. In HEK293 cells which do not overexpress folate receptors, positively 
charged BHS interact with the negatively charged cell membrane. The high MFI values 
obtained for this cell line suggests that BHS bind to the cell membrane through the 
electrostatic interaction or are taken up inside the cell through the endocytosis process. In 
SBC-2 cells which overexpress folate receptors, BHS can bind to the cell membrane or be 
taken up through the endocytosis process similarly as in HEK293 cells. The higher MFI values 
obtained in SBC-2 cells are due to the possibility of cellular uptake via the recognition of folic 
acid by folate receptors present on the cell membrane. Once folate conjugates are bound to a 
cell surface folate receptors, they are transported into the cell through a process called 
receptor-mediated endocytosis by engulfing inside the endosome. In SBC-2 cells, 
internalization inside the cell is a competition between charge-driven and folate-mediated 
uptake. 
 
Figure 36: Cell internalization pathways for HEK293 and SBC-2 cells. 
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Higher uptake in the purified samples suggests that the free folate groups present in the non-
purified solution occupy part of the folate receptors and do not allow the BHS to enter the cell. 
The MFI for SBC-2 cells obtained by the BHS modified with the high ratio of folic acid, 
namely 1/1/10 and 1/1/8, was much lower compared with the non-modified BHS and BHS 
modified with Folate2k in the ratio 1/1/6 and 1/1/2. Interestingly, the MFI results obtained for 
the HEK293 cells were similar. It can mean that too high number of the spacers attached to the 
BHS causes the steric problems for the folic acid to reach the folate receptors expressed on the 
cancer cell. Additionally, the high number of spacers surrounding the BHS can contribute to 
the shielding effect of the positive charge of BHS which will decrease the cellular uptake. The 
other possibility is that all of the binding pockets of SA were saturated and high number of 
free folate groups that were not removed during the purification step caused the receptors 
blocking (Figure 35).  
 
Figure 37: Cellular uptake of HEK293 cells after different incubation times. BHS2k = PEI-
biotin/SA/Folate2k, non-pur. = non-purified. 
In Figure 37 the time dependency of molecular uptake in HEK293 cells for different structures 
is presented. The molecular uptake for all the systems increases with the longer incubation 
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time. The highest MFI values were obtained for the purified BHS modified with different 
folate ratios (1/1/10, 1/1/8, 1/1/6 and 1/1/2). Values of the purified samples were always 
higher compared with the non-purified ones. It means that free folate groups present in the 
solution not only decrease the uptake in the cancer cells but can also contribute to the lower 
uptake in the normal cells due to generating the stealth properties. In HEK293 cells the 
cationic charge is a driving force for the molecular uptake of BHS inside the cells or 
interaction with the membrane.  
 
Figure 38: Cellular uptake of SBC-2 cells after different incubation times. BHS2k = PEI-
biotin/SA/Folate2k, non-pur. = non-purified. 
Figure 38 presents the cellular uptake of SBC-2 cells incubated with different BHS modified 
with Folate2k. For all the time points the highest uptake in cancer cells was obtained for non-
modified BHS and BHS modified with Folate2k in the ratios 1/1/6 and 1/1/2. For the 
structures with the other folate ratios, the uptake was lower compared with non-modified 
BHS. As explained earlier, the molecular uptake in cancer cells incubated with BHS modified 
with too high amounts of folate is decreased. The highest MFI was obtained for the structures 
with the ratio 1/1/6 and this system was chosen for the next experiments. In SBC-2 cells the 
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there is a competition between the charge-driven interaction with the cell membrane surface 
and folate-mediated uptake inside the cell. 
5.3. BHS modified with long folate moieties 
In order to investigate the influence of folate chain length, similar experiments were 
performed with the modification of BHS with the folate ligand of the mass 5000 Da. 
Structures with different molar ratios of PEI-biotin/SA/Folate5k were prepared, namely 
1/1/10, 1/1/8, 1/1/6, 1/1/2 and 1/1/1. Additionally the cellular uptake after incubation with 
only Folate5k and the conjugation of SA/Folate5k was tested. The importance of the 
purification step was also investigated. Figure 39 shows the results of molecular uptake after 
incubation with different BHS modified with long folate ligands. 
 
Figure 39: Cellular uptake after incubation with BHS modified with Folate5k or single 
components for 1 h. BHS5k = PEI-biotin/SA/Folate5k, non-pur. = non-purified 
Similarly as for the short chains, the MFI values obtained for Folate5k and SA/Folate5k are 
very low for both cell lines. The results obtained for the modified BHS are much higher, 
which again shows the synergetic characteristics of biohybrid materials. The molecular uptake 
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after incubation with BHS modified with Folate5k was always higher for the cancer cells 
compared to the normal cells. Among the BHS modified with Folate5k with different folate 
ratios, the highest molecular uptakes of SBC-2 cells were achieved after incubation with PEI-
biotin/SA/Folate5k 1/1/6 and 1/1/2, however the values are lower than for the non-modified 
BHS. The MFI values for the HEK293 cells are in the similar range for non-modified and all 
BHS modified with Folate5k. It showed that addition of the long ligands terminated with folic 
acid did not increase the molecular uptake in cancer cells. The 5000 Da chains are very long 
and possess backfolding properties. They start to behave like coil-structures where the 
terminating folic acid is not exposed at the surface of BHS and is not able to reach the folate 
receptors of the cancer cell. 
 
Figure 40: Cellular uptake of HEK293 cells after different incubation times. BHS5k = PEI-
biotin/SA/Folate5k, non-pur. = non-purified 
Figure 40 presents the time-dependency of the cellular uptake of HEK293 cells after the 
incubation with different BHS modified with Folate5k. For all the time points the MFI value 
for all the structures was in the similar range, however always a little bit higher for the non-
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modified BHS and BHS modified with Folate5k which were purified. In general for the 
normal cells there were no significant differences recorded between the non-modified BHS 
and BHS modified with Folate5k. 
In Figure 41 the comparison of cellular uptake of SBC-2 cells incubated with different BHS 
modified with Folate5k is presented. As can be clearly observed, for all the time points the 
MFI values obtained for all the BHS modified with Folate5k are much lower compared with 
the non-modified BHS. The values obtained for SBC-2 cells after the incubation with non-
modified BHS are much higher than for HEK293 cells. For the modified structures the 
differences in the values between the cancer and normal cells are not very radical.   
 
Figure 41: Cellular uptake of SBC-2 cells after different incubation times. BHS5k = PEI-
biotin/SA/Folate5k, non-pur. = non-purified 
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5.4. Comparison between the BHS modified with short and long folate 
moieties 
In order to choose the best system for the future biomedical application, the comparison 
between the results obtained for the BHS modified with Folate2k and Folate5k was performed. 
For the structures with lower and medium ratios of folate, namely PEI-biotin/SA/Folate 1/1/6, 
1/1/2 and 1/1/1, the results look similar and are illustrated by example of the purified 1/1/6 
samples in Figure 42. For HEK293 cells, the MFI values obtained for the BHS modified with 
Folate2k and with Folate5k are very similar. There are no significant differences in the 
molecular uptake of normal cells after modification with the chains of different lengths. For 
SBC-2 cells the differences in the uptake are striking. After the short incubation times, the 
MFI values obtained for the BHS modified with 2k moieties are similar to the values obtained 
for the BHS modified with 5k moieties. However, after the longer incubation times, the results 
measured for BHS-Folate2k are around two times higher compared with the values obtained 
for BHS-Folate5k.  
 
Figure 42: Cellular uptake of HEK293 and SBC cells after incubation with purified PEI-
biotin/SA/Folate 1/1/6 with different chain lengths after different incubation times 
The situation of the cellular uptake between the BHS modified with folate chains of different 
lengths looked distinct after incubation with the structures with the higher folate ratios (1/1/8 
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and 1/1/10) what is presented in Figure 43. In such a case, there are no differences between the 
BHS modified with Folate2k and with Folate5k. The results obtained for both of the cell lines 
are in the same range. It means that too high amounts of the added folate moieties cause the 
steric problems and folic acid is not exposed to reach the folate receptors on the cancer cell. 
The binding pockets of SA are fully saturated and not available for the further modifications. 
It suggests that unknown molecular rearrangement takes place. With too many folate moieties 
shielding effect of BHS also contributes to the decreased molecular uptake.   
As the results obtained for the BHS-Folate2k for medium amounts of folate are the most 
promising, only the samples of BHS modified with Folate2k with the ratio 1/1/6 were chosen 
for the next studies of the molecular uptake mechanism. 
 
Figure 43: Cellular uptake of HEK293 and SBC cells after incubation with purified PEI-
biotin/SA/Folate 1/1/10 with different chain lengths after different incubation times. 
5.5. BHS modified with Biotin-PEG and BHS modified with folate 
In order to investigate the real influence of addition of folic acid groups, BHS were modified 
with Biotin-PEG chain of the same lengths as folate groups. The only difference between BHS 
modified with Biotin-PEG and modified with folate is the presence of the folic acid molecules 
at the end of the chains. Folic acid should enhance the cellular uptake in cancer cells due to the 
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successful recognition by the folate receptors overexpressed on the SBC-2 cells. BHS were 
modified with Biotin-PEG and with folate of the lengths 2 kDa and 5 kDa in the ratio 1/1/6. 
The overview of the structures is presented in Figure 44. Additionally, the influence of 
purification step was investigated. In Figure 45, the comparison between non-modified BHS, 
BHS modified with folate and BHS modified with Biotin-PEG is presented. 
 
Figure 44: The overview of different modifications of BHS. 
 
The highest MFI for SBC-2 cells was obtained for the purified BHS-Folate2k and the value is 
much higher compared with the purified BHS-Biotin-PEG. The MFI values obtained for those 
structures for HEK293 cells are very similar. Increased uptake in the cancer cells and no 
difference in the normal cells prove that presence of folic acid significantly increases the 
uptake in cancer cells due to the successful recognition by folate receptors and the possibility 
to enter inside the cell through the folate receptor mediated endocytosis process in addition to 
the non-receptor mediated uptake (charge-driven interaction with the cell membrane).  
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Figure 45: Cellular uptake after incubation with BHS modified with folate and Biotin-PEG 
for 8h. BHS = PEI-biotin/SA, non-pur. = non-purified. 
Comparing the results for the short chain non-purified samples of BHS-Folate and BHS-
Biotin-PEG, it can be seen that the molecular uptake in cancer cells was very similar for both 
of the structures. It means that free folate groups present in the non-purified sample block the 
folate receptors on the surface of the cancer cell and the uptake will be similar to the structures 
without the presence of folic acid. For the BHS modified with longer chains, the outcome is 
different than for the BHS modified with shorter ligands. After incubation with BHS modified 
with 5k chains, the molecular uptake is similar for the structures with folate and Biotin-PEG. 
It confirms that 5 kDa chains are too long and the back folding of the ligand appears. The 
chain behaves like a coil and terminating folate groups are not available for the binding 
pockets. Folic acid is not able to reach the folate receptors and the molecular uptake is not 
increased. It means that internalization inside the cell is non-receptor mediated (only charge-
driven uptake via interaction with the cell membrane).  
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Figure 46: Cellular uptake of HEK293 cells after different incubation times 
In Figure 46 the comparison of molecular uptake of HEK293 cells incubated with different 
BHS is presented. For all the structures the cellular uptake increases with the incubation time. 
The highest MFI values were obtained for non-modified BHS and purified BHS modified with 
Folate2k. Values obtained for the other BHS modified with folate and BHS modified with 
Biotin-PEG were in the similar range after all the time points.  
Figure 47 shows the comparison of molecular uptake in SBC-2 cells after incubation with 
different BHS. The highest cellular uptake was achieved after the incubation with purified 
BHS modified with Folate2k and was significantly higher compared to the BHS modified with 
Biotin-PEG2k after every time point. For the BHS modified with longer spacers, it can be seen 
that MFI values obtained after modification with folate and Biotin-PEG are very similar for all 
the incubation times. This proves the back folding of the chain and unavailability of the folic 
acid to reach the folate receptors.  
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Figure 47: Cellular uptake of SBC-2 cells after different incubation times 
 
5.6. Cellular uptake mechanism 
To analyze the cell uptake mechanism of BHS, the flow cytometry experiments in the 
presence of inhibitor of endocytosis were performed. Mammalian cells use different 
endocytotic pathways for the internalization of nanoscaled particles, which can be 
distinguished between clathrin-dependent, caveolin-dependent and clathrin- and caveolin-
independent endocytosis as presented in Figure 48. Clathrin-dependent endocytosis acts 
through the formation of clathrin-coated vesicles from clathrin-coated pits, which then form 
endosomes and fuse with lysosomes.[70] Chlorpromazine, which interferes with the 
intracellular clathrin processing, is an inhibitor of this mechanism[22] and was employed here.  
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Figure 48: Clathrin-dependent and -independent internalization pathways.[71] 
 
Different concentrations of chlorpromazine were added to the cell culture medium before 
incubation with BHS. The absence of cytotoxic effects which may otherwise influence 
subsequent analysis of uptake mechanisms was confirmed (the results shown in appendix on 
the page 88). The measurements were performed for non-modified BHS and BHS modified 
with Folate2k. Figure 49 presents the results obtained for non-modified BHS. There are no 
significant differences between the results obtained for the structures incubated with and 
without the presence of inhibitor in both cell lines. It means that internalization of BHS inside 
the cell does not take place through the clathrin-dependent endocytosis. It probably happens 
through the clathrin-independent process, cellular uptake is non-specific or BHS was bound to 
the cellular membrane and did not translocate inside the cell. 
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Figure 49: Cellular uptake after incubation with non-modified BHS incubated and different 
concentrations of inhibitors of endocytosis for 0.5 h. chl. = chlorpromazine 
. 
 
Figure 50: Cellular uptake after incubation with BHS modified with Folate2k and different 
concentrations of inhibitors of endocytosis for 2 h. BHS2k = PEI-biotin/SA/Folate2k, chl. = 
chlorpromazine 
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In the next step similar experiment was performed with BHS modified with Folate2k. 
Additionally, in order to verify that enhanced uptake of folic acid-containing BHS was 
mediated by folate receptors on the cancer cells, free folate was added to the cell culture 
medium before incubation with BHS. As shown in Figure 50, similarly to non-modified BHS, 
the uptake of both cell lines was not inhibited after incubation with chlorpromazine and the 
cellular uptake is not mediated through the clathrin-dependent endocytosis. The uptake of 
SBC-2 cells was significantly reduced when the folate receptors were blocked with free folic 
acid, whereas the uptake of HEK-293 cells was not decreased. Accordingly, blocking of the 
folate receptors in SBC-2 cells inhibited the folate-receptor mediated endocytosis process 
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IV. Conclusion 
The aim of the thesis was the fabrication and characterization of biohybrid structures (BHS) 
with defined size based on streptavidin (SA) and pentavalent biotinylated dendritic 
glycopolymer through non-covalent SA-biotin conjugation and further functionalization with 
biotinylated PEGylated folic acid for the selective targeting to tumor cells. It was 
demonstrated that the use of polyassociation reaction allows the formation of BHS with the 
control over their sizes. Modification with folic acid via another biotin-streptavidin 
conjugation does not cause the disaggregation of the structures and the long term stability 
properties were confirmed. Addition of free biotin molecules or biotin-PEG12 eventually 
caused the rearrangement of the structure due to a slight change in size but no degradation to 
initial components took place. Zeta potential measurements showed that the surface charge of 
BHS is slightly cationic.  
The cytotoxicity of the BHS was investigated. It was shown that fabricated BHS are 
biocompatible, with regard to both normal and cancer cells. Modification with folic acid or 
biotin-PEG did not cause toxicity to the cells.  
In the flow cytometry studies it was demonstrated that the molecular uptake of cancer cells 
incubated with BHS is up to two times higher compared with the normal cells. It showed that 
BHS are suitable materials as nanocarriers for the selective targeting to tumor cells. After 
incubation with the single components of the structures the cellular uptake was very low, 
however, using BHS it was significantly higher. It proved that BHS are extraordinary 
materials with synergetic functions that combine the features of both natural and synthetic 
components resulting with outstanding properties. Modification of BHS with folic acid ligand 
of short length with the ratio 1/1/6 increased the molecular uptake in cancer cells compared 
with the non-modified BHS. As the cellular uptake in normal cells was similar, it was proved 
that folic acid is a tumor-targeting agent, because it enhances the cellular uptake in cancer 
cells due to the successful recognition of folic acid by the folate receptors overexpressed on 
the cancer cells. It was shown that the cationic charge of BHS is a driving force of 
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internalization inside the cell or interaction with the negatively charged cellular membrane of 
normal cells, while internalization inside the cancer cell is a competition between the charge-
driven and folate-mediated endocytosis process.  
Furthermore, the impact of the purification step was investigated. It was demonstrated that 
after incubation with purified samples the molecular uptake in cancer cells was higher than 
without the purification. The presence of free folate groups in the solution leads to the 
occupation of the folate receptors and prevents the BHS from entering inside the cell. 
 
Figure 51: Summary of the influencing key points in the conjugation of biotinylated dendritic 
glycopolymers and streptavidin 
Additionally, the direct influence of folic acid was analyzed by comparison of the cellular 
uptake after incubation with BHS modified with biotin-PEG-folic acid and BHS modified with 
biotin-PEG-COOH. It was shown that after modification with chains of short length, the 
uptake in cancer cells is significantly higher for the structures containing folic acid, whereas in 
normal cells is similar. After modification with chains of higher molar mass, the uptake in 
both cell lines was at the same level for both biotin-PEG-folic acid and biotin-PEG-COOH 
modifications. Modifying with short length biotin-PEG-folic acid moiety, folic acid is exposed 
at the surface of the structure and is able to directly interact with the folate receptors 
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expressing tumor cells. Modification with long length moiety results in backfolding of the 
chain and folic acid is not available to bind to the cell. When high number of folate molecules 
saturates all the residual binding pockets of SA, the shielding effect of BHS appears and the 
uptake is decreased. Figure 51 provides a summary of the main points investigated in the flow 
cytometry experiments. In the last step, the mechanism of cellular uptake was investigated. It 
was proved that both non-modified and modified with folate BHS are not taken up inside the 
cell through the clathrin-dependent endocytosis process. Future experiments are necessary to 
investigate the uptake mechanism of BHS. Additionally, BHS modified with folate were 
incubated with free folate molecules in order to prove receptor blocking. The uptake was 
decreased which proved that free folate present in the solution inhibited the folate-receptor 
mediated endocytosis process. 
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V. Experimental section  
1. Reagents and materials 
Modification of hyperbranched poly(ethylene imine) with maltose and biotinylation were 
performed by the working group as previously described by Appelhans et al.[14] and Ennen et 
al.[59].  
 
Table 4. List of the used substances and their suppliers 
Substance Supplier 
Hyperbranched poly(ethylene imine) with Mw 25000 g∙mol-1 
Streptavidin 
Neutravidin 
Folic acid-PEG-biotin with Mw 2000 g∙mol-1 
Folic acid-PEG-biotin with Mw 5000 g∙mol-1 
Biotin-PEG-COOH with Mw 2000 g∙mol-1 
Biotin-CONH-PEG-COOH with Mw 5000 g∙mol-1 
Biotin 
Biotin-PEG12-COOH 
Biotin-4-Fluorescein 
Phosphate buffered saline (PBS) 
Dulbecco’s modified eagle medium (DMEM) 
Dulbecco’s Phosphate Buffered Saline (DPBS) 
Trypsin-EDTA (0.05 %) 
AlamarBlue cell viability reagent 
Dialysis tubes from Cellulose Ester (MWCO 20000 Da) 
Chlorpromazine hydrochloride 
BASF SE 
Prozyme 
Thermofisher 
Nanocs 
Nanocs 
Creative PEGWorks 
RAPP Polymere 
Sigma Aldrich 
Iris Biotech GMBH 
Sigma Aldrich 
Sigma Aldrich 
Life Technologies 
Life Technologies 
Life Technologies 
Thermofisher 
SpectrumLabs 
Sigma Aldrich 
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2. Instruments 
2.1. Dynamic light scattering and zeta potential 
Characterization of the particle size, size distribution and zeta potential was performed using 
Nano Zetasizer (Malvern Instruments Ltd), equipped with a He-Ne laser (4 mW) and a digital 
autocorrelator. The measurements were carried out at 25°C at a fixed angle of 173°.  
In the size measurements the disposable plastic cuvettes (PLASTIBRAND, UV) of BRAND 
GmbH&Co. KG, Wertheim, Germany with 1cm pathlength were used.  
 
For the zeta potential measurement the disposable folded capillary cells of Malvern 
Instruments were used. 
2.2. UV-Vis spectroscopy 
UV/Vis spectra were recorded at room temperature (25 °C) on Specord 20 Plus UV/Vis 
spectrometer (Analytik Jena AG). 
All photometric measurements were performed in quartz microcuvettes. 
2.3. Cell culture 
All the experiments with cell cultures were performed in laminar flow work bench Laminair 
HB2472 (Heraeus Instruments GmbH). Cells were kept in the BBD 6220 CO2 incubator 
(Thermo Scientific Heraeus) under constant conditions at 37 °C in 5% CO2 atmosphere.  
2.4. Cytotoxicity 
Fluorescence intensities in the cytotoxicity experiments were recorded on Synergy 2 Multi-
Mode Reader (BioTek Instruments) at room temperature (25 °C).  
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2.5. Flow cytometry  
Flow cytometry experiments were performed on MACSQuant® Analyzer 10 (Miltenyi Biotec) 
which is equipped in three lasers (violet, blue and red with excitation wavelengths 405nm, 
488nm and 635nm, respectively) and 10 optical channels. 
3. Formation of biohybrid structures 
The general protocol for the preparation of BHS consisted of few steps. First step included the 
preparation of SA and PEI-biotin solutions which were kept overnight before the assembling 
of BHS. The solvent of the BHS formation was phosphate buffered saline (PBS). The next day, 
the solutions of SA and PEI-biotin were filtered with 0.1 and 0.25 μm filters, respectively, and 
mixed for the assembling process of BHS. The solutions were let to equilibrate for 24 hours at 
7 °C. After the assembling process of BHS was finished, the modification with folate was 
done by mixing solutions in the required ratios. After the assembling time of 18 hours, the 
characterization of modified BHS could be performed. If the purification step was required, 
samples were purified in a dialysis process. Samples were placed inside the membrane with 
the cut-off of 20 kDa and dialyzed against PBS solution under constant stirring for 24 hours. 
Amount of folate that was flashed out during the dialysis was controlled through UV-Vis 
measurement. Absorption spectra were recorded before and after the dialysis and the 
comparison of absorbance values at 350 nm and 500 nm enabled the estimation of the sample 
dilution during the dialysis and the amount of folate that was bound to BHS (data not shown).  
The molar concentrations used for preparation of BHS for DLS measurements are presented in 
Table 5. Volume used for the measurement was 500 μl. For the experiments with the excess of 
biotin, free biotin or biotin-PEG12 in the corresponding concentrations were added to the 
solution of BHS 24 hours after assembling of the structures. The PEI-biotin/SA/Folate molar 
ratios used for all the experiments are presented in Table 6. For the zeta potential 
measurements, the solutions of BHS were prepared with the SA concentration c=2.5 mol∙L-1 
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and corresponding PEI-biotin and folate concentrations in Millipore water and purified in 
distilled water for 24 h.  
Table 5. Molar concentrations used for fabrication of BHS in DLS measurements. 
 cSA, mol∙L-1 
cPEI-biotin, 
mol∙L-1 
cFolate, mol∙L-1 
Total mass 
concentration, 
mg∙ml-1 
SA 7.5 0 0 0.655 
PEI-biotin 0 10 0 0.743 
SA/PEI-biotin 1/0.5 2.5 1.25 0 0.311 
SA/PEI-biotin 1/1 2.5 2.5 0 0.404 
SA/PEI-biotin 1/2 2.5 5 0 0.590 
PEI-biotin/SA/Folate2k 1/1/6 2.5 2.5 15 0.434 
PEI-biotin/SA/Folate5k 1/1/6 2.5 2.5 15 0.479 
 
For the cytotoxicity measurements the solution of BHS with the highest concentration (c=2.5 
g∙L-1) was prepared and the samples with smaller concentrations were obtained by dissolution 
of the highest concentrated sample in PBS.  
For the flow cytometry experiment, the solutions were prepared in a way that the final mass 
concentration of each sample was 200 μg∙mL−1. Staining of the samples with fluorescent dye 
was desired to conduct the experiment. In the measurements of single components, PEI-biotin 
and SA labeled with fluorescein isothiocyanate (FITC) were used. PEI-biotin was labeled with 
SCN-FITC during the formation process and SA was stained by mixing with the biotin-FITC 
solution in the molar ratio 1/1. Modification of PEI-biotin with FITC was performed by 
Johannes Fingernagel, member of Dr Appelhans group. The samples of folate were not labeled, 
because folic acid exhibits fluorescent behavior. BHS samples used in the flow cytometry 
were fabricated with the use of PEI-biotin stained with FITC and non-labeled SA. 
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Table 6. Molar ratios of the PEI-biotin/SA/Folate and PEI-biotin/SA/biotin-PEG used in 
different experiments. 
BHS DLS Zeta potential Cytotoxicity Flow cytometry 
SA/PEI-biotin 1/0.5, 1/1, 1/2 - 1/1 1/1 
PEI-biotin/SA/Biotin 
1/1/1, 1/1/2, 1/1/4, 
1/1/10, 1/1/50 and 
1/1/100 
- -- - 
PEI-biotin/SA/Biotin-
PEG12 
1/1/1, 1/1/2, 1/1/4, 
1/1/10, and 1/1/100 
- - - 
PEI-biotin/SA/Folate2k 1/1/6 1/1/6 1/1/6 
1/1/1, 1/1/2, 1/1/6, 
1/1/8 and 1/1/10 
PEI-biotin/SA/Folate5k 1/1/6 1/1/6 1/1/6 
1/1/1, 1/1/2, 1/1/6, 
1/1/8 and 1/1/10 
PEI-biotin/SA/biotin-
PEG2k 
- - 1/1/6 1/1/6 
PEI-biotin/SA/biotin-
PEG5k 
- - 1/1/6 1/1/6 
 
4. Characterization of biohybrid structures  
4.1.  Dynamic light scattering 
To characterize the particle size and size distribution, DLS measurements were performed in 5 
runs, with 12 x 10 seconds. Thus only measurements with a good fit and an exponential 
graphic representation were considered here. The results were analyzed by merging identical 
curves from different measurement runs. The particle size distribution was determined using a 
multimodal peak analysis by volume. 
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4.2. Zeta potential 
Zeta potential measurements conditions were 3 runs with 50 x 1 second at 40V. The solutions 
used for titration were 0.1M HCl and NaOH.  
4.3. Cell culture  
Human Embryonic Kidney 293 cells (HEK293) and Human Cervix Carcinoma cells (SBC-2, 
derivative of HELA) were obtained from Neurosurgery Department, University Hospital Carl 
Gustav Carus, Germany. Cells were cultured in DMEM growth medium supplemented with 10% 
(v/v) fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units mL−1 penicillin 
and 100 μg mL−1 streptomycin. Cell were grown in a humidified incubator at 37 °C in 5% CO2 
atmosphere. The medium was replaced every two days and cells were subcultured by 
trypsinization.  
4.4. Cytotoxicity assay  
HEK293 and SBC-2 cells were seeded in a 96-well plate at an initial density of 2×104 cells per 
well in 200 μL of complete DMEM medium. After 24 h incubation cell culture medium was 
replaced with 200 μL of DMEM containing the corresponding BHS with the desired 
concentrations for further 24 h. AlamarBlue reagent (10% v/v) was added to each well and 
cells were further incubated for 4 h at 37 °C. Finally, the fluorescence intensities were 
recorded by a microplate reader. Each experiment was done in triplicate and the data are 
shown as the mean value plus standard deviation (SD). 
4.5. Flow cytometry  
HEK293 and SBC-2 cells were seeded at density of 2×105 cells per well in 1,5 ml of complete 
DMEM medium in a 12-well plate and incubated for 24 h. Cells were then incubated with 1 
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ml of DMEM containing 200 μg mL−1 of the corresponding sample at 37°C in a humidified 5% 
CO2 incubator. After desired incubation time, cells were washed with PBS and harvested by 
trypsinization followed by centrifugation at 1100 rpm for 5 min at 4°C. The resulting pellets 
were resuspended in 200 μL PBS and analyzed by the flow cytometer. A minimum of 3×104 
cells have been analyzed for each sample and the data was analyzed by FlowJo software. 
For the experiments of cellular uptake mechanism, cells were incubated for 1 hour with the 
cell culture medium containing the corresponding concentration of chlorpromazine. 
Afterwards, medium was replaced with DMEM containing chlorpromazine and corresponding 
BHS. For the experiments of receptors blocking, cells were incubated with cell culture 
medium containing 200 μg mL−1 of folic acid-PEG-biotin. After 30 minutes, BHS were added 
and the instruction was followed as for the previous experiments.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
VI. References 
[1] Abbasi, E.; Aval, S. F.; Akbarzadeh, A.; Milani, M.; Nasrabadi, H. T.; Joo, S. W.; 
Hanifehpour, Y.; Nejati-Koshki, K.; Pashaei-Asl, R. Dendrimers: synthesis, applications, and 
properties. Nanoscale Research Letters 2014, 9. 
[2] Dykes, G. M. Dendrimers: a review of their appeal and applications. Journal of 
Chemical Technology and Biotechnology 2001, 76, 903-18. 
[3] Carlmark, A.; Hawker, C. J.; Hult, A.; Malkoch, M. New methodologies in the 
construction of dendritic materials. Chemical Society Reviews 2009, 38, 352-62. 
[4] Buhleier, E.; Wehner, W.; Vogtle, F. Cascade-Chain-Like and Nonskid-Chain-Like 
Syntheses of Molecular Cavity Topologies. Synthesis-Stuttgart 1978, 155-58. 
[5] Fischer, M.; Vogtle, F. Dendrimers: From design to application - A progress report. 
Angewandte Chemie-International Edition 1999, 38, 885-905. 
[6] Nanjwade, B. K.; Bechra, H. M.; Derkar, G. K.; Manvi, F. V.; Nanjwade, V. K. 
Dendrimers: Emerging polymers for drug-delivery systems. European Journal of 
Pharmaceutical Sciences 2009, 38, 185-96. 
[7] Jang, W. D.; Selim, K. M. K.; Lee, C. H.; Kang, I. K. Bioinspired application of 
dendrimers: From bio-mimicry to biomedical applications. Progress in Polymer Science 2009, 
34, 1-23. 
[8] Holter, D.; Burgath, A.; Frey, H. Degree of branching in hyperbranched polymers. 
Acta Polymerica 1997, 48, 30-35. 
[9] Gillies, E. R.; Frechet, J. M. J. Dendrimers and dendritic polymers in drug delivery. 
Drug Discovery Today 2005, 10, 35-43. 
77 
 
[10] Cheng, Y. Y.; Man, N.; Xu, T. W.; Fu, R. Q.; Wang, X. Y.; Wang, X. M.; Wen, L. P. 
Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine 
(PAMAM) dendrimers. Journal of Pharmaceutical Sciences 2007, 96, 595-602. 
[11] Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. In vitro evaluation of 
dendrimer prodrugs for oral drug delivery. International Journal of Pharmaceutics 2007, 336, 
183-90. 
[12] Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A. K.; 
Thomas, T.; Mule, J.; Baker, J. R. Design and function of a dendrimer-based therapeutic 
nanodevice targeted to tumor cells through the folate receptor. Pharmaceutical Research 
2002, 19, 1310-16. 
[13] Yemul, O.; Imae, T. Synthesis and characterization of poly(ethyleneimine) dendrimers. 
Colloid and Polymer Science 2008, 286, 747-52. 
[14] Appelhans, D.; Komber, H.; Quadir, M. A.; Richter, S.; Schwarz, S.; van der Vlist, J.; 
Aigner, A.; Muller, M.; Loos, K.; Seidel, J.; Arndt, K. F.; Haag, R.; Voit, B. Hyperbranched 
PEI with Various Oligosaccharide Architectures: Synthesis, Characterization, ATP 
Complexation, and Cellular Uptake Properties. Biomacromolecules 2009, 10, 1114-24. 
[15] Fischer, D.; Bieber, T.; Li, Y. X.; Elsasser, H. P.; Kissel, T. A novel non-viral vector 
for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of 
molecular weight on transfection efficiency and cytotoxicity. Pharmaceutical Research 1999, 
16, 1273-79. 
[16] Liang, B.; He, M. L.; Xiao, Z. P.; Li, Y.; Chan, C. Y.; Kung, H. F.; Shuai, X. T.; Peng, 
Y. Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-
targeted gene delivery. Biochemical and Biophysical Research Communications 2008, 367, 
874-80. 
[17] Rudd, P. M.; Wormald, M. R.; Dwek, R. A. Sugar-mediated ligand-receptor 
interactions in the immune system. Trends in Biotechnology 2004, 22, 524-30. 
78 
 
[18] Gorelik, E.; Galili, U.; Raz, A. On the role of cell surface carbohydrates and their 
binding proteins (lectins) in tumor metastasis. Cancer and Metastasis Reviews 2001, 20, 245-
77. 
[19] Veronese, F. M.; Pasut, G. PEGylation, successful approach to drug delivery. Drug 
Discovery Today 2005, 10, 1451-58. 
[20] Appelhans, D.; Klajnert-Maculewicz, B.; Janaszewska, A.; Lazniewska, J.; Voit, B. 
Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic 
approaches, characteristics and potential for biomedical applications. Chemical Society 
Reviews 2015, 44, 3968-96. 
[21] Klajnert, B.; Appelhans, D.; Komber, H.; Morgner, N.; Schwarz, S.; Richter, S.; 
Brutschy, B.; Ionov, M.; Tonkikh, A. K.; Bryszewska, M.; Voit, B. The influence of densely 
organized maltose shells on the biological properties of poly(propylene imine) dendrimers: 
New effects dependent on hydrogen bonding. Chemistry-a European Journal 2008, 14, 7030-
41. 
[22] Hobel, S.; Loos, A.; Appelhans, D.; Schwarz, S.; Seidel, J.; Voit, B.; Aigner, A. 
Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): 
Physicochemical and biological properties of DNA and siRNA complexes. Journal of 
Controlled Release 2011, 149, 146-58. 
[23] Sakahara, H.; Saga, T. Avidin-biotin system for delivery of diagnostic agents. 
Advanced Drug Delivery Reviews 1999, 37, 89-101. 
[24] Livnah, O.; Bayer, E. A.; Wilchek, M.; Sussman, J. L. 3-Dimensional Structures of 
Avidin and the Avidin-Biotin Complex. Proceedings of the National Academy of Sciences of 
the United States of America 1993, 90, 5076-80. 
[25] Livnah, O.; Bayer, E. A.; Wilchek, M.; Sussman, J. L. The Structure of the Complex 
between Avidin and the Dye, 2-(4'-Hydroxyazobenzene) Benzoic-Acid (Haba). Febs Letters 
1993, 328, 165-68. 
79 
 
[26] Fingernagel, J. Untersuchung von Biohybridstrukturen auf Basis von Glycopolymeren 
und Albuminbindungsdomänen unter Nutzung von Nickel (II)– Nitrilotriessigsäure– Histidin 
und Biotin– Avidin Wechselwirkungen. Master thesis, Technische Universität Dresden, 2013. 
[27] Dundas, C. M.; Demonte, D.; Park, S. Streptavidin-biotin technology: improvements 
and innovations in chemical and biological applications. Applied Microbiology and 
Biotechnology 2013, 97, 9343-53. 
[28] Bruch, R. C.; White, H. B. Compositional and Structural Heterogeneity of Avidin 
Glycopeptides. Biochemistry 1982, 21, 5334-41. 
[29] Weber, P. C.; Ohlendorf, D. H.; Wendoloski, J. J.; Salemme, F. R. Structural Origins 
of High-Affinity Biotin Binding to Streptavidin. Science 1989, 243, 85-88. 
[30] Vermette, P.; Gengenbach, T.; Divisekera, U.; Kambouris, P. A.; Griesser, H. J.; 
Meagher, L. Immobilization and surface characterization of NeutrAvidin biotin-binding 
protein on different hydrogel interlayers. Journal of Colloid and Interface Science 2003, 259, 
13-26. 
[31] Technical data sheet 779.; The benefits of neutravidin over streptavidin and avidin. 
Polysciences, Inc., 2008. 
[32] Sinha, R.; Kim, G. J.; Nie, S. M.; Shin, D. M. Nanotechnology in cancer therapeutics: 
bioconjugated nanoparticles for drug delivery. Molecular Cancer Therapeutics 2006, 5, 1909-
17. 
[33] Hilgenbrink, A. R.; Low, P. S. Folate receptor-mediated drug targeting: From 
therapeutics to diagnostics. Journal of Pharmaceutical Sciences 2005, 94, 2135-46. 
[34] Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential Regulation of Folate Receptor 
Isoforms in Normal and Malignant-Tissues in-Vivo and in Established Cell-Lines - 
Physiological and Clinical Implications. Cancer 1994, 73, 2432-43. 
80 
 
[35] Weitman, S. D.; Weinberg, A. G.; Coney, L. R.; Zurawski, V. R.; Jennings, D. S.; 
Kamen, B. A. Cellular-Localization of the Folate Receptor - Potential Role in Drug Toxicity 
and Folate Homeostasis. Cancer Research 1992, 52, 6708-11. 
[36] Cole, A. J.; Yang, V. C.; David, A. E. Cancer theranostics: the rise of targeted 
magnetic nanoparticles. Trends in Biotechnology 2011, 29, 323-32. 
[37] Bailey, L. B.; Gregory, J. F. Folate metabolism and requirements. Journal of Nutrition 
1999, 129, 779-82. 
[38] Stanger, O. Physiology of folic acid in health and disease. Current Drug Metabolism 
2002, 3, 211-23. 
[39] Marchetti, C.; Palaia, I.; Giorgini, M.; De Medici, C.; Iadarola, R.; Vertechy, L.; 
Domenici, L.; Di Donato, V.; Tomao, F.; Muzii, L.; Panici, P. B. Targeted drug delivery via 
folate receptors in recurrent ovarian cancer: a review. Oncotargets and Therapy 2014, 7, 1223-
36. 
[40] Leamon, C. P.; Low, P. S. Delivery of Macromolecules into Living Cells - a Method 
That Exploits Folate Receptor Endocytosis. Proceedings of the National Academy of Sciences 
of the United States of America 1991, 88, 5572-76. 
[41] Wang, Z. L.; Xu, B.; Zhang, L.; Zhang, J. B.; Ma, T. H.; Zhang, J. B.; Fu, X. Q.; Tian, 
W. J. Folic acid-functionalized mesoporous silica nanospheres hybridized with AIE 
luminogens for targeted cancer cell imaging. Nanoscale 2013, 5, 2065-72. 
[42] Jung, C. W.; Jalani, G.; Ko, J.; Choo, J.; Lim, D. W. Synthesis, Characterization, and 
Directional Binding of Anisotropic Biohybrid Microparticles for Multiplexed Biosensing. 
Macromolecular Rapid Communications 2014, 35, 56-65. 
[43] Rao, S. Y.; Guo, Z. B.; Liang, D. W.; Chen, D. L.; Wei, Y.; Xiang, Y. A 
proteorhodopsin-based biohybrid light-powering pH sensor. Physical Chemistry Chemical 
Physics 2013, 15, 15821-24. 
81 
 
[44] Sapsford, K. E.; Algar, W. R.; Berti, L.; Gemmill, K. B.; Casey, B. J.; Oh, E.; Stewart, 
M. H.; Medintz, I. L. Functionalizing Nanoparticles with Biological Molecules: Developing 
Chemistries that Facilitate Nanotechnology. Chemical Reviews 2013, 113, 1904-2074. 
[45] Park, I. K.; Von Recum, H. A.; Jiang, S. Y.; Pun, S. H. Supramolecular assembly of 
cyclodextrin-based nanoparticles on solid surfaces for gene delivery. Langmuir 2006, 22, 
8478-84. 
[46] Loftsson, T.; Duchene, D. Cyclodextrins and their pharmaceutical applications. 
International Journal of Pharmaceutics 2007, 329, 1-11. 
[47] Granadero, D.; Bordello, J.; Perez-Alvite, M. J.; Novo, M.; Al-Soufi, W. Host-Guest 
Complexation Studied by Fluorescence Correlation Spectroscopy: Adamantane-Cyclodextrin 
Inclusion. International Journal of Molecular Sciences 2010, 11, 173-88. 
[48] Paolino, M.; Ennen, F.; Lamponi, S.; Cernescu, M.; Voit, B.; Cappelli, A.; Appelhans, 
D.; Komber, H. Cyclodextrin-Adamantane Host-Guest Interactions on the Surface of 
Biocompatible Adamantyl-Modified Glycodendrimers. Macromolecules 2013, 46, 3215-27. 
[49] Koopmans, C.; Ritter, H. Formation of Physical Hydrogels via Host-Guest Interactions 
of beta-Cyclodextrin Polymers and Copolymers Bearing Adamantyl Groups. Macromolecules 
2008, 41, 7418-22. 
[50] Scott, J. K.; Loganathan, D.; Easley, R. B.; Gong, X. F.; Goldstein, I. J. A Family of 
Concanavalin a-Binding Peptides from a Hexapeptide Epitope Library. Proceedings of the 
National Academy of Sciences of the United States of America 1992, 89, 5398-402. 
[51] Yin, R. X.; Tong, Z.; Yang, D. Z.; Nie, J. Glucose and pH dual-responsive 
concanavalin A based microhydrogels for insulin delivery. International Journal of Biological 
Macromolecules 2011, 49, 1137-42. 
[52] Zempleni, J.; Wijeratne, S. S. K.; Hassan, Y. I. Biotin. Biofactors 2009, 35, 36-46. 
[53] Ennen, F.; Boye, S.; Lederer, A.; Cernescu, M.; Komber, H.; Brutschy, B.; Voit, B.; 
Appethans, D. Biohybrid structures consisting of biotinylated glycodendrimers and proteins: 
82 
 
influence of the biotin ligand's number and chemical nature on the biotin-avidin conjugation. 
Polymer Chemistry 2014, 5, 1323-39. 
[54] Wilchek, M.; Bayer, E. A.; Livnah, O. Essentials of biorecognition: The (strept)avidin-
biotin system as a model for protein-protein and protein-ligand interaction. Immunology 
Letters 2006, 103, 27-32. 
[55] Hnatowich, D. J.; Virzi, F.; Rusckowski, M. Investigations of Avidin and Biotin for 
Imaging Applications. Journal of Nuclear Medicine 1987, 28, 1294-302. 
[56] Lillich, M.; Chen, X.; Weil, T.; Barth, H.; Fahrer, J. Streptavidin-Conjugated C3 
Protein Mediates the Delivery of Mono-Biotinylated RNAse A into Macrophages. 
Bioconjugate Chemistry 2012, 23, 1426-36. 
[57] Qu, W.; Qin, S. Y.; Kuang, Y.; Zhuo, R. X.; Zhang, X. Z. Peptide-based vectors 
mediated by avidin-biotin interaction for tumor targeted gene delivery. Journal of Materials 
Chemistry B 2013, 1, 2147-54. 
[58] Pulkkinen, M.; Pikkarainen, J.; Wirth, T.; Tarvainen, T.; Haapa-Acho, V.; Korhonen, 
H.; Seppala, J.; Jarvinen, K. Three-step tumor targeting of paclitaxel using biotinylated PLA-
PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro 
anticancer activity. European Journal of Pharmaceutics and Biopharmaceutics 2008, 70, 66-
74. 
[59] Ennen, F.; Fenner, P.; Boye, S.; Lederer, A.; Komber, H.; Voit, B.; Appelhans, D. 
Sphere-Like Protein-Glycopolymer Nanostructures Tailored by Polyassociation. 
Biomacromolecules 2016, 17, 32-45. 
[60] Gun'ko, V. M.; Klyueva, A. V.; Levchuk, Y. N.; Leboda, R. Photon correlation 
spectroscopy investigations of proteins. Advances in Colloid and Interface Science 2003, 105, 
201-328. 
[61] Brar, S. K.; Verma, M. Measurement of nanoparticles by light-scattering techniques. 
Trac-Trends in Analytical Chemistry 2011, 30, 4-17. 
83 
 
[62] Glawdel T.; Ren C. (2008) Zeta Potential measurement. In Encyclopedia of 
Microfluidics and Nanofluidics. (pp 2199-2207); Li D.; Springer 
[63] Rampersad, S. N. Multiple Applications of Alamar Blue as an Indicator of Metabolic 
Function and Cellular Health in Cell Viability Bioassays. Sensors 2012, 12, 12347-60. 
[64] Brown, M.; Wittwer, C. Flow cytometry: Principles and clinical applications in 
hematology. Clinical Chemistry 2000, 46, 1221-29. 
[65] Picot, J.; Guerin, C. L.; Kim, C. L. V.; Boulanger, C. M. Flow cytometry: 
retrospective, fundamentals and recent instrumentation. Cytotechnology 2012, 64, 109-30. 
[66] Torchilin, V. P. Passive and Active Drug Targeting: Drug Delivery to Tumors as an 
Example. In Drug Delivery, Schäfer-Korting, M., Ed. Springer Berlin Heidelberg: Berlin, 
Heidelberg, 2010; pp 3-53. 
[67] Torchilin, V. P. Targeting of Drugs and Drug Carriers within the Cardiovascular-
System. Advanced Drug Delivery Reviews 1995, 17, 75-101. 
[68] Capco, D. G.; Chen, Y. S. Nanomaterial: Impacts on Cell Biology and Medicine. 
Springer: 2014. 
[69] Ahn, S.; Seo, E.; Kim, K.; Lee, S. J. Controlled cellular uptake and drug efficacy of 
nanotherapeutics. Scientific Reports 2013, 3. 
[70] Brodsky, F. M.; Chen, C. Y.; Knuehl, C.; Towler, M. C.; Wakeham, D. E. Biological 
basket weaving: Formation and function of clathrin-coated vesicles. Annual Review of Cell 
and Developmental Biology 2001, 17, 517-68. 
[71] McMahon, H. T.; Boucrot, E. Molecular mechanism and physiological functions of 
clathrin-mediated endocytosis. Nature Reviews Molecular Cell Biology 2011, 12, 517-33. 
 
 
84 
 
VII. Appendix 
 
Figure 52: Long term stability study of the non-modified BHS consisted of SA/PEI-biotin 
1/0.5. 
 
Figure 53: Long term stability study of the non-modified BHS consisted of SA/PEI-biotin 1/2. 
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Figure 54: Long term stability study of the purified BHS modified with Folate2k. 
 
 
Figure 55: Long term stability study of the non-purified BHS modified with Folate2k. 
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Figure 56: Long term stability study of the non-purified BHS modified with Folate5k. 
 
 
Figure 57: Zeta potential of BHS modified with Folate5k. 
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Figure 58: Viability of HEK293 cells after 24 hours incubation with different structures. 
 
 
Figure 59: Viability of SBC-2 cells after 24 hours incubation with different structures. 
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Figure 60: Viabilities of HEK293 and SBC-2 cells treated for 24h with different 
concentrations of chlorpromazine. 
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